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HOW MUCH ANXIETY 
"There is a common tendency in our day, both 
on the part of professional psychologists and laymen, 
to look upon anxiety as a negative, destructive, 
"abnormal" experience, one which must be fought 
and if possible annihilated .... " 
0 . H. Mowrer 1 
Since 1950 the literature on anxiety, both 
professional and lay, has increased a thousandfold in 
the form of articles, symposia, reports and scientific 
exhibits. And virtually all of this output reflects a 
common presumptioq-that anxiety is a negative, 
nonproductive experience. This viewpoint leads nat-
urally to a discussion of how to combat or eliminate 
anxiety. 
But anxiety, as Mowrer implies, has its uses. 
It can play a positive and constructive role in human 
development. Without it neither an individual nor a 
society can grow. 
Productive vs. 
nonproductive anxiety: 
a matter of degree 
For the physician the difference is not an 
academic one. He must distinguish between produc-
tive and nonproductive anxiety. And the difference 
is often one of degree. 
In low levels of anxiety, for example, the indi-
vidual is alert and sensitive to threats and acquires 
an increased ability to cope. Performance is often 
improved. 2 
But at higher levels of anxiety the opposite is 
true.2 The ability to distinguish between the danger-
ous and the trivial is reduced and often leads to 
inappropriate behavior. Apprehension becomes fear . 
And coping becomes difficult, if not impossible. 
Crossing the 
anxiety threshold 
The key question for the physician then be-
comes: Is the degree of anxiety experienced produc-
tive or nonproductive for the individual patient? 
And while some patients may require relatively large 
amounts of anxiety to perform optimally, for others 
lower levels of anxiety may prove unproductive. 
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INTRODUCTION 
In this issue, the MCV Quarterly continues to 
publish selected papers presented at the recent 
Postgraduate Course in Nuclear Medicine sponsored 
by the Department of Radiology of the Medical Col-
lege of Virginia. The papers reflect modern in vitro 
and in vivo radioactive isotope applications. Once 
again the authors deserve our thanks for their 
enlightening contributions. 
KLAUS RANNIGER, M.D. 
Professor and Chairman 
Department of Radiology 
Medical College of Virginia 
Virginia Commonwealth University 
Scintiphotography 
Transplants 
HALCOTT T. HADEN, M.D. 
lll Evaluation of Renal 
Associate Professor of Radiology and Medicine, Chief. Nuclear Medicine Section, McGuire VA Hospital, Rich-
mond. Virginia 
Renal -transplantation has progressed from the 
research stage to become a standard clinical 
procedure. Although still generally limited to large 
medical centers, renal transplants are regularly done 
in over 135 hospitals in the United States. In 1972, 
approximately 2,600 renal transplants were recorded 
in the United States by the Renal Transplant Reg-
istry (1 ). Approximately 65% of these were cadaver 
donors and 35% living donors. 
The kidney transplant recipient is subject to a 
variety of complications, especially during the early 
post-transplant period. Radionuclide scintiphotog-
raphy has been found to be a valuable method for 
evaluation of renal transplant function and for 
detection of some of the more frequent complica-
tions (2,3,4,5). Because of this, scintiphotography 
now has a major role in transplant evaluation. This 
paper will review the radionuclide procedures avail-
able and their current use in evaluation of renal 
transplants. 
Scintigraphic Procedures. The transplanted kid-
ney is routinely placed in the iliac fossa. This loca-
tion allows the kidney, ureter, and bladder to be 
included in the field of view of a standard scintilla-
tion camera. The procedures currently in use are: 
I. kidney and bladder scintigraphy using 1311-
orthoiodohippurate. 
2. scintigraphy of blood flow distribution fol-
lowed by kidney and bladder imaging using 
99mTc-Sn-DTPA. 
3. scintigraphy using 99mTc-sulfur colloid. 
Presented by Dr. Haden a t the Postgraduate Course in 
Nuclear Medicine, February 27, 1975, in Williamsburg, Virginia. 
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4. scintigraphy combined with transplant 
renogram or other function studies. 
Jodine-131-hippurate scintigraphy. Scintiphoto-
graphs of the kidney and bladder area are obtained 
approximately every 4 minutes for 20 to 30 minutes. 
If the bladder is filled, the patient then voids or the 
catheter is undamped and a post-voiding picture is 
obtained. In a normal study there should be uniform 
maximum concentration in the renal parenchyma at 4 
minutes with excretion into the bladder at 8 minutes 
and decreasing renal concentration by 20 minutes. 
Figure I shows an example of a normal study. 
Perfusion sequence and scintigraphy with 99mTc-
Sn-DTPA . This tracer is excreted exclusively by 
glomerular filtration and is not as rapidly Cleared 
from plasma as is hippurate. Sufficient radioactivity 
can be given to visualize the major vessels and renal 
perfusion if rapid sequential scintiphotos are ob-
tained immediately after a bolus injection. A normal 
study of this type is seen in Figure 2. If renal function 
is good, there will be rapid excretion of the tracer and 
subsequent scintiphotos will show the kidney and 
urinary tract as seen in Figure 3. If renal function is 
moderately impaired, however, excretion becomes 
markedly delayed and may not be adequate for 
visualization. Hippurate may still give adequate 
visualization in this case, so that hippurate remains 
the most dependable tracer for routine use, even 
though Tc-Sn-DTPA may in some cases give better 
visualization. 
Scintigraphy with 99mTc-sulfur colloid. Colloidal 
tracers are not normally concentrated in the kidney. 
However, when the changes of chronic rejection 
develop, colloidal tracers are localized to some extent 
IOI 
102 
Fig I-Normal scintiphotographic transplant study using '"1-
hippurate. Kidney is seen in first picture and ureter and bladder are 
visualized in later pictures. Time periods are indicated. 
in the kidney and can be demonstrated on scin-
tiphotography. One technique is to use a diverging 
collimator so as to include the bony pelvis but ex-
clude the liver image (6). The concentration in the 
kidney is then compared with that in the bones. An 
example of this study in two separate patients is 
shown in Figure 4. Both patients had mild to 
moderate chronic rejection but well-preserved renal 
function . We have not found this study to be very 
useful since it does not dependably detect acute rejec-
tion and almost all of the transplants eventually 
develop some degree of chronic rejection. 
Scintigraphy combined with renogram or other 
function studies. Scintigraphy with 1311-hippurate 
provides only a crude and semiquantitative measure 
Fig 3- Normal scintigraphic transplant study of excretion phase 
using ••mTc-Sn-DTPA. Kidney, ureter, and bladder are clearly 
seen. 
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Fig 2-Scintiphotos from a transplant perfusion study using 
••mTc-Sn-DTPA. Terminal aorta, iliac arteries, and transplanted 
kidney are seen. 
of renal function. A transplant renogram can be ob-
tained simultaneously and gives an additional 
method of comparing serial studies but is cumber-
some to obtain with standard equipment. If the in-
travenous dose is precisely measured and subsequent 
blood and urine collection are made, the effective 
renal plasma flow may be calculated. The value of 
these additional measurements is not established and 
they are not routinely used. 
Disorders of Transplant Function. The main 
criterion for satisfactory transplant function is an 
adequate urine output. Serious complications are 
usually manifested by a decrease in urine output. 
Fig 4- Scintiphotographs of transplanted kidney after I. V. injec-
tion of ••mTc-sulfur colloid. Two separate patients. On the left, 
concentration is seen in the lumbar spine, pelvis, and in the kidney 
in the right iliac fossa. On the right, the kidney concentration is so 
much greater than the bones that pelvis, spine, and upper femur 
are only very faintly seen. 
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Table I gives a list of the common causes of acute 
oliguria in transplant recipients. When oliguria oc-
curs, the cause must be promptly determined as a 
guide to effective treatment. 
Acute tubular necrosis is the most common 
cause of acute oliguria following soon after 
transplantation, especially with cadaver transplants, 
and is completely reversible with adequate treatment. 
If associated with the transplant procedure, this com-
plication occurs within the first 48 hours after sur-
gery. Acute rejection, obstructing clots, and ureteral 
leaks are also common. Arterial and venous occlu-
sion are uncommon, and we have not yet had cortical 
necrosis occur. Lymphocele is a collection of lymph 
adjacent to the transplanted kidney which may occur 
following interruption of lymphatics in that area. 
Lymphoceles usually cause compression or displace-
ment of the ureter and bladder and may produce 
urinary obstruction. They do not occur until after the 
first week and may not develop until six to eight 
months after transplantation. 
Diagnostic Studies for Acute Oliguria. The 
various causes of oliguria listed in Table I cannot be 
differentiated on a clinical basis. Prompt diagnosis is 
obviously of critical importance since the treatment 
for each cause is different and may entail additional 
risk. The order of diagnostic studies used by M. J. V. 
Smith, MD, of the Medical College of Virginia 
Urology Division is given in Table 2 (7) (oral com-
munication, February, 1975). 
The first item on this list, the one-hour biopsy, 
refers to a kidney biopsy obtained at the end of the 
TABLE I 
Causes of Acute Oliguria in Renal Transplant 
Vascular 
Arterial thrombosis 
Venous thrombosis 
Parenchymal 
Acute tubular necrosis 
Acute rejection 
Cortical necrosis 
Ureter 
Clots 
Leaks 
Edema at anastomosis 
Necrosis and retraction 
Bladder 
Leaks or perforations 
General 
Lymphocele 
TABLE 2 
Acute Oliguria in Renal Transplant 
Order of Diagnostic Studies 
I. one-hour biopsy 
2. irrigate catheter 
3. KUB x-ray 
4. scintigram 
5. cystogram 
6. cystoscopy 
a. bulb retrograde 
b. catheter retrograde 
7. arteriography 
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transplant procedure. This may show early evidence 
of acute rejection. The first four steps on this list are 
without risk and often give sufficient diagnostic in-
formation to determine treatment. The subsequent 
procedures should be performed only if necessary 
because of added risk, especially since these patients 
all receive aggressive immunosuppressive therapy. 
Scintigraphic Findings in Transplant Disorders. A 
brief tabulation of the scintigraphic findings in 
transplant disorders is given in Table 3. 
A cute tubular necrosis. With acute tubular 
necrosis the kidney will still concentrate hippurate in 
the renal parenchyma, although the concentration is 
somewhat decreased and maximum concentration is 
delayed. Typically, no excretion into renal pelvis or 
Normal 
TABLE 3 
Scintiphotography of Renal Transplants 
Using 131 l-Orthoiodohippurate 
Uniform maximum concentration in renal 
parenchyma at 4 minutes 
Excretion into bladder by 8 minutes 
Decreasing renal concentration by 20 minutes 
Acute Tubular Necrosis 
Delayed concentration 
No excretion 
Acute Rejection 
Delayed concentration 
Irregular concentration 
Delayed excretion 
Acute Tubular Necrosis with Added Rejection 
Delayed irregular concentration compared 
with baseline 
U reteral Obstruction 
Retention of tracer proximal to obstruction 
Ureteral Leak 
Tracer outside urinary tract 
Vascular Occlusion- Arterial 
No activity in kidney 
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Fig 5-Selected scintigraphs obtained in a patient with two 
transplanted kidneys studied with 1311-hippurate. Both kidneys are 
seen. The kidney on the patient's right (observer's left) was 
transplanted 15 months previously and is the site of severe chronic 
rejection. The other kidney was inserted one day previously and is 
not functioning because of acute tubular necrosis. 
bladder is visualized. Figure 5 shows pictures selected 
from a series of scintigraphs obtained because of 
severe oliguria one day after transplantation of a sec-
ond kidney into the left iliac fossa. The first kidney 
was inserted 15 months previously on the right side 
and had developed severe chronic rejection. The re-
jected kidney is visualized on the patient's right 
(observer's left) as an area of poor concentration sug-
gesting a small kidney. The new transplant is well 
visualized on the patient's left (observer's right), but 
maximum concentration is definitely delayed and no 
excretion from the kidney is seen even after 30 
minutes. Within a week there was good function ·of 
the new kidney. 
Rejection. Rejection may be of varying acuteness 
and severity. Hyperacute rejection occurs im-
mediately after transplantation and is associated with 
severe acute inflammatory and vascular changes in 
the kidney. Thrombosis of small vessels occurs, and 
on scintigraphic study the findings may be the same 
as in arterial occlusion. The transplanted kidney must 
always be removed following hyperacute rejection. 
Rejection of less severity may occur at any time fol-
lowing transplantation. This reaction may develop 
quite abruptly and may cause sudden oliguria. On 
scintigraphic study, acute rejection produces delayed 
and sometimes irregular concentration of hippurate. 
Excretion is also delayed or may be absent. Figures 6 
and 7 show scintigraphic studies of a patient who 
received a transplant on 5 December, 1974. The scin-
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Fig 6-Transplant scintigraphic study four days post-transplant 
with good function. 
tigraphic study on 9 December, 1974, (Fig 6) shows 
that the kidney is working quite well. On 11 
December, 1974, the patient developed sudden 
oliguria, and a repeat study on that day is shown in 
Figure 7. Concentration is delayed and there is no ex-
cretion. These findings are compatible with either 
acute tubular necrosis or acute rejection. However, 
the time after transplantation and the demonstration 
of good function two days previously exclude acute 
tubular necrosis resulting from the transplant 
procedure as a cause of the acute oliguria. This 
patient was treated for acute rejection with resulting 
improvement. 
Chronic rejection is associated with delayed con-
centration and delayed excretion as shown in Figure 
8. These findings are not specific for chronic rejection 
since they may occur with other chronic parenchymal 
disease of the kidney. Concentration of colloidal par-
Fig 7-Same patient as Fig. 6 two days later. Acute rejection. 
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Fig 8-Sulfur colloid and hippurate scintigraphs in chronic rejec-
tion. 
tides can be demonstrated in chronic rejection, but 
this has not been particularly helpful since essentially 
all of the transplants develop some degree of chronic 
rejection. 
Rejection may be of varying degree and may oc-
cur in combination with acute tubular necrosis or 
other disorders. This may be quite difficult to detect. 
However, any deterioration of renal function on scin-
tigraphic study after the first 24 hours usually in-
dicates rejection. It is, therefore, good practice to ob-
tain an initial scintigraphic study at 24 to 48 hours 
after transplantation as a baseline for subsequent 
studies. Changes due to acute tubular necrosis will be 
maximal at 24 hours. 
Ureteral obstruction. The ureter may be 
obstructed early by clots or later by stones or by com-
pressing lesions such as lymphoceles. As long as renal 
parenchymal function remains good there will be 
good concentration of hippurate by the kidney. Scin-
tigraphic study shows accumulation of tracer prox-
imal to the obstruction with delayed or absent excre-
tion into the bladder. An example of partial obstruc-
tion of the upper ureter is shown in Figure 9. 
Ureteral leaks. Extravasation of urine from the 
ureter or from the ureterovesical junction is a com-
mon and serious complication of renal transplanta-
tion. It has occurred in 8% to 30% of several series 
with a mortality rate of 25% to 50%. Ureteral leak is 
readily demonstrable by scintigraphic study, but one 
must be careful to follow the study long enough to 
fully evaluate any unusual appearance. It is also wise 
to obtain post-voiding films to clearly establish blad-
der location. Figure 10 shows several pictures from a 
study obtained one month after transplantation. The 
105 
Fig 9-Partial ureteral obstruction producing retention in pelvis 
and upper ureter, delayed visualization of bladder. 
patient had increasing serum creatinine, but no local 
signs and was thought to have mild rejection. An ab-
normal collection is seen adjacent to the bladder in 
the early pictures, and at 25 minutes there is a wide 
area of abnormal concentration extending along the 
path of the ureter. The picture at two hours shows the 
radioactivity located in extravasated urine collected 
around the bladder, ureter, and lower pole of the 
kidney. The IO-minute picture also shows some reten-
tion of tracer in the renal pelvis and collecting system 
suggesting mild partial obstruction associated with 
the urinoma. 
Vascular occlusion. With arterial occlusion the 
kidney is not perfused and no tracer is concentrated 
in the kidney. Using 99mTc-pertechnetate or DTPA, 
the major vessels can be visualized and the lack of 
perfusion can be demonstrated as shown in the top 
Fig IO-Progressive urine extravasation from ureterovesical junc-
tion. 
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half of Figure 11. When hippurate is the tracer, scin-
tiphotos over the kidney simply show no concentra-
tion in the renal parenchyma as at the bottom of 
Figure 11. These findings may occur in primary 
arterial occlusion or in hyperacute rejection with 
thrombosis of small vessels. In either case, surgery is 
required for removal of the kidney unless a vascular 
occlusion can be repaired. Venous occlusion, if com-
plete, will block vascular perfusion and is usually fol-
lowed by thrombosis in the arterial supply. However, 
venous thrombosis may partially block vascular fl.ow 
and the kidney may survive after a period of 
decreased function. If there is viable and perfused 
renal tissue still present then there should be some 
concentration of hippurate. It is generally felt, 
though not completely proven, that the absence of 
any demonstrable concentration of hippurate in-
dicates that the kidney is no longer viable and should 
be removed. 
Management of Transplant Oliguria Based on 
Scintigraphic Findings. When oliguria develops in the 
transplant recipient, the results of the scintigraphic 
study together with clinical findings will usually in-
dicate the management to be followed. This is briefly 
summarized in Table 4. If the oliguria develops 
within the first 48 hours and the scintigram shows a 
clear renal image with decreased excretion, manage-
ment for acute tubular necrosis is indicated. If the 
time period is not compatible with acute tubular 
necrosis or if subsequent scintigrams show further 
deterioration, then rejection has developed. If there is 
no renal image with hippurate or technetium, then 
Fig I I- Arterial occlusion . U pper pictures with "mTc-
pertechnetate show terminal aorta and iliac arteries with " cold" 
area over kidney. Lower pictures made with 1311-hippurate show no 
concentration in kidney. 
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TABLE 4 
H ippurate Scintiphotography in Management of 
Acute Oliguria in Renal Transplants 
I. Clear renal image with decreased excretion: 
Conservative Management 
A. If image deteriorates on subsequent study: 
Treat Rejection 
2. No renal image: 
Study with Pertechnetate Bolus 
A. If no perfusion: 
Arteriogram or Surgery 
3. Ureteral obstruction: 
Retrograde or J.V. Urogram or Surgery 
4. Extravasation: 
Retrograde Urogram or Surgery 
surgery is required. An arteriogram can be done if it 
is necessary to differentiate between hyperacute rejec-
tion and arterial occlusion. U reteral obstruction will 
usually be evident on the scintigraph, but further 
diagnostic procedures will be required to determine 
the cause. Extravasation will also be evident on the 
scintigraph, but further studies will be required to 
localize the precise site and extent. In some cases, ex-
travasation can be treated without surgery if infection 
does not develop. 
Conclusions. 
I . Scintiphotography of the kidney and bladder 
using 1311-hippurate is the basic procedure for 
transplant evaluation. This is a dependable 
method for determining transplant viability 
and function. It is also a dependable method 
for detecting ureteral leak or obstruction, 
provided that renal function is adequate. 
2. Concentration of hippurate indicates that the 
kidney has a blood supply, is viable, and has 
recoverable function. Absence of hippurate 
concentration indicates severe and probably 
irreversible kidney damage. 
3. Scintiphotography with 99mTc-Sn-DTPA 
gives good resolution in normally functioning 
kidneys. With severely impaired renal func-
tion, this tracer is inferior to 131I-hippurate. 
4. Rapid sequence scintigraphy of the initial cir-
culation using technetium tracers can 
visualize major vessels . and renal perfusion. 
Quantitation and comparison between 
studies are difficult. 
5. A single scintiphotographic study will not 
differentiate between acute tubular necrosis 
and rejection. Serial scintiphotographic 
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studies may indicate rejection if deterioration 
of function is shown to occur later than 24 
hours after transplantation. 
6. Colloidal tracers may concentrate in the 
kidney in chronic rejectjon. This phenome-
non has not yet been clinically helpful. 
7. The scintigraphic findings in transplant dis-
orders have been reviewed and a schema for 
management based on these findings has been 
presented. 
Figures l and 3 are reprinted from the Journal of Nuclear 
Medicine, Vol. 16, No. 7, with permission of publisher. 
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Use of Bone Scanning and Skeletal Radiography 
in the Diagnosis of Bone Metastasis 
JAY C. MALL, M .D. AND PAUL B. HOFFER, M .D . 
Department of Radiology, University of California Medical Center, San Francisco, California 
The radionuclide bone scan is becoming in-
creasingly useful for evaluating a wide variety of bone 
and joint disorders. However, the commonest ap-
plication is still the detection of skeletal metastases in 
the patient with known or suspected neoplastic dis-
ease. The role of this examination relative to other 
well established methods of evaluating these patients, 
especially the radiographic skeletal survey, is not 
clear to all physicians. We hope in this communica-
tion to define the role of the radionuclide bone scan 
and to place in perspective the integral relationship 
between the "scan" and the "survey," the two 
radiologic modalities which today are the principal 
methods of evaluating the skeletal system for 
metastatic disease. 
Radiopharmaceuticals. Historically, numerous 
agents have been used for bone scanning, but only a 
small number have been applicable for general 
clinical use. The first of these were the strontium 
isotopes, strontium-85 and strontium-87m. Subse-
quently, fiuorine- 18 and, most recently, the 
technetium-99m-labeled phosphate compounds have 
been used . 
Strontium. Strontium is an analogue of calcium 
and, as such, is incorporated into the hydroxyapatite 
crystal by an ion-exchange process with calcium (I) . 
Unfortunately, the plasma clearance of strontium is 
slow due to partial binding with plasma proteins (2, 
3). Excretion occurs by both urinary tract and bowel 
(4). 
Strontium-85 nitrate was one of the first agents 
used for imaging of bone lesions. Its long physical 
Presented by Dr. Hoffer at the Postgraduate Course in 
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half-life of 65 days severely limited the administered 
dose, which was usually 100 microcuries. The pres-
ence of bowel activity in the first few days follow-
ing injection necessitated cleansing enemas and/ or 
long delays between isotope administration and scan. 
Its 514 kev photon was also much higher than ideal 
for nuclear imaging instrumentation. Nevertheless, 
85Sr was a clinically useful bone scanning agent. 
Strontium-87m has a considerably shorter phys-
ical half-life (2.8 hours) and lower photon energy (388 
kev) making it a physically more desirable agent. 
Unfortunately, the high body-background during the 
first 12 hours following injection results in less than 
optimal clinical images (2) and, therefore, this agent 
has not been widely used for bone imaging. 
Fluorine-18. Fluorine-18 is a hydroxyl analogue 
which is incorporated into bone by an ion-exchange 
process forming a fiuorapatite crystal (I, 5). Bone has 
a very high affinity for fluorine with most of the 
radionuclide extracted from the blood on the initial 
transit (2, 5). The renal extraction efficiency is also 
high and, therefore, plasma clearance of 18F is the 
most rapid of any of the clinically useful bone scan-
ning radionuclides (6,7). Excellent bone-to-back-
ground . ratios can be obtained with 18F at 1 to 2 
hours following intravenous injection (3, 6) . The half-
life is very short ( 1.8 hours) which is advantageous 
from the standpoint of patient dose. However, the 
short half-life of 18 F is also a problem because it is 
cyclotron-produced (8) and, therefore, its use is 
limited to those locations in close proximity to a 
cyclotron . The 511 kev annihilation radiation from 
18 F makes imaging with the gamma camera difficult. 
The best images are obtained with a rectilinear scan-
ner or special positron camera (5, 9). Transportation 
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problems and cost, both related to the short half-life 
of 18F, have inhibited its clinical use. 
Technetium-99m-labeled compounds. This group 
of compounds contains the phosphate polymers, 
pyrophosphate and polyphosphate, and their organic 
analogues, the diphosphonates. These agents localize 
Fig I- Decreased uptake in Ilium (arrow) in patient with 
metastatic bone lesion. Such "photopenic" lesions occur as a result 
of lack of hyperemic response to tumor due to debilitation , failure 
of tumor to provoke response, or radiation to region of lesion. 
in bone crystal by surface chemisorption rather than 
ionic exchange ( l 0, 11 ). The terminal phosphate 
groups of the 99mTc-labeled compound react with the 
"phosphate gaps" which are present in the imperfect 
bone crystals. (The 99mTc acts only as a label unlike 
18F and the Sr isotopes). Plasma clearance varies 
' 
Fig 2- Diffuse increase in skeletal activity denoted by "absence" 
of renal activity. In addition to diffuse metastasis, the absent 
kidney sign may also be seen in severe renal disease, hyper-
parathyroidism and hypermetabolic states. 
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TABLE I 
Bone Scans vs. Skeletal Survey 
for the Detection of Metastatic Lesions to Bone 
Radionuclide 
No. of + scan -scan 
Source pts. -x-ray + x-ray 
Sr DeN ardo (l 966) 84 38% 4% 
DeNardo et al. (1972) 
Briggs (l 967) 83 20% 1% 
Bessler ( 1968) 104 15% 1% 
Harmer et al. (l 969) 47 41 % 6% 
Legge et al. ( 1970) 186 13% 2% 
G nekow et al. ( 1972) 353 8% 2% 
18f1 Harmer et al. ( 1969) 112 31 % 3% 
Blau et al. (1972) 239 15% 4.5% 
Hopkins et al. (1972) 104 20% 4% 
Merrick (1973) 119 13% 0 
99mTc Desaulhiers (1973) 100 9% 1% 
Pendergrass (1973) 259 20% 2% 
Citrin et al. (1974) 70 10% 0 
Barrett and Smith (l 974) 90 71 % (of 2% 
lesions) 
among the principal agents comprising this group 
with the diphosphonates being cleared most rapidly, 
pyrophosphate cleared somewhat less rapidly, and 
polyphosphates being cleared least rapidly (7) . The 
bone-to-background ratios achieved with the 
diphosphonates at 3 hours is almost comparable to 
TABLE 2 
Bone Scan vs. Skeletal Survey For Specific Tumor Types 
Source 
Breast 
Sklaroff and Charkes ( 1968) 
Galasko (1969) 
Galasko ( 1971) 
Marty and Hoffman (1972) 
Lung 
Sauerbrum et al (l 972) 
Shirazi et al ( 1973) 
Prostate 
Morgan and Mills (1968) 
Williams et al (1968) 
Roy et al (1971) 
Shearer et al (1974) 
Bisson et al (1974) 
Lymphoma 
Weber et al ( 1968) 
Harbert and Ashburn ( 1968) 
Moran et al (1973) 
+scan -scan 
# ofpts. - x-ray + x-ray 
64 
100 
164 
82 
206 
66 
70 
30 
61 
81 
19 
51 
80 
16% 
29% 
26% 
30% 
7% 
42% 
21% 
53% 
12% 
27% 
74% 
12% 
5% 
0 
0 
0 
1% 
0 
0 
0 
1% 
1% 
0 
4% 
0 
that achieved with 18F at l to 2 hours (6, 7). Other ad-
vantages of this group of agents are the short half-life 
of 99mTc (6 hours) which permits the safe administra-
tion of millicurie doses and .near optimal gamma 
energy (140 kev) and high photon flux which make 
possible rapid performance of the procedure and 
good spatial resolution with the gamma camera, the 
most widely used nuclear imaging device. The ready 
availability and easy preparation from commercial 
kits with a long shelf-life also make them ideal for 
general clinical use. The 99mTc-labeled compounds 
are the current agents of choice for bone scanning. 
The availability of these excellent and convenient 
agents has fostered the recent widespread clinical 
popularity of bone scanning. 
"Scans Signs" of Tumor. Considerable lab-
oratory data has accumulated over the past years 
indicating that the two principal factors involved in 
the uptake of bone-seeking radionuclides into the 
bone are 1) bone blood flow and 2) metabolic activity 
of the bone ( 10, 12, 13 ). Recent evidence has in-
dicated that for 18F and the 99mTc-labeled phosphate 
compounds, bone blood fl.ow is the most important 
factor (I 0). 
The detection of metastatic tumor in bone is 
based on the premise that the destructive and 
reparative events that occur in the bone as a result of 
a metastatic deposit cause a localized increase in 
blood fl.ow and bone turnover. This in turn results in 
localized increased uptake of the bone scanning agent 
which is imaged as a "hot spot" on the bone scan. 
This "hot spot" can usually be easily recognized by 
an alteration in the bilateral symmetry or, as with 
the axial skeleton, an alteration of the homogeneous 
uptake in the spine. A second "scan sign" of tumor 
involvement is a localized area of decreased uptake of 
the bone scanning agent (Fig !). This has been re-
ferred to as a "photon deficient" or "photopenic" ab-
normality and occurs in cases where there is replace-
ment of a portion of bone by tumor with little or no 
reparative response on the part of the host because of 
the nature of the tumor or the debilitated state of the 
patient (14 ). (Similar findings noted by R. S. Hatt-
ner, MD, unpublished data.) This is a distinctly less 
common sign of skeletal involvement than a localized 
area of increased uptake. A third "scan sign" of met-
astatic involvement of the skeleton is diffuse but uni-
form increased uptake which does not alter the bi-
lateral symmetry and may only be recognized by the 
decrease in renal activity (Fig 2) (15). Normally, the 
kidneys in adult patients can be clearly identified at 
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3 to 4 hours following administration of the 99mTc 
compounds. The absence of renal activity is a rare 
but important manifestation of metastatic skeletal in-
volvement which occurs when so much of the radio-
nuclide is deposited in bone that virtually none is 
available to be localized in the kidney. In some re-
ported series, this "scan sign" was unrecognized and 
such cases were termed false-negative (16, 17). 
Comparison of Bone Scan to Bone Survey. Many 
clinical studies have been performed comparing the 
relative sensitivity of the radionuclide bone scan and 
the radiographic skeletal survey for the detection of 
skeletal metastases. In earlier reports, 85Sr and 87mSr 
were the isotopes used for radionuclide bone scan-
ning, but in more recent reports 18F and 99mTc-labeled 
phosphate compounds have been employed. These 
studies are summarized in Table 1 (5, 18-28). All of 
these studies indicate that the radionuclide bone scan 
is more sensitive than the radiographic skeletal sur-
vey for detecting skeletal metastases. Some reports 
indicate that the results with 99mTc-labeled phosphate 
compounds are even better than with 18F or the Sr 
agents (26-31 ). For certain common neoplasms, a 
particularly large experience has accrued over the 
years to compare the two techniques of bone scan-
ning and skeletal survey on a tumor-oriented basis. 
These comparisons are summarized in Table 2 (32-
45) and as noted by E. M. Moran, MD (oral 
communication, June, 1973 ). 
Although it is quite clear that the radionuclide 
bone scan is more sensitive than the radiographic 
skeletal survey for detecting skeletal metastases, it is 
important to remember that the examination is non-
specific in nature. Focal areas of increased 
radionuclide uptake in bone are invariably due to 
some skeletal abnormality; however, it must be noted 
that the scan can be "positive" in numerous condi-
tions other than neoplasm (Fig 3A and 38) (46, 47). 
Table 3 is a list of non-neoplastic conditions which 
cause focal increase in radionuclide uptake in bone. 
The radiograph, on the other hand, while not as sen-
sitive, is quite specific and may exhibit characteristic 
patterns which allow for a more accurate etiologic 
diagnosis. For these reasons, a radiograph is always 
necessary to assess the significance of a scan abnor-
mality. 
False-negative radionuclide bone scans occur in-
frequently, in approximately 0.4% of patients in most 
of the recent studies as noted in Tables 1 and 2. These 
have been seen to occur in certain specific situa-
tions ( 17,48-50). They are: 1) Some patients with 
' 
Fig 3A-Abnormal bone scan revealing increased radionuclide 
uptake in the left clavicle and proximal right tibia. 
myeloma; 2) some patients with tumor of anaplastic 
cell type; 3) some severely debilitated patients with 
poor host response; 4) patients with diffuse disease 
uniformly involving the whole skeleton; 5) patients 
with pelvic lesions obscured by a high level of activity 
in the bladder; 6) lesions that have been irradiated. 
As to the incidence of false-positive bone scans, in 
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Fig 38-Radiograph of clavicle reveals coarsened trabecular pattern and sclerosis typical of Paget's disease. 
those clinical studies in which lesions detected by 
scan but not by x-ray were evaluated by follow-up x-
rays, biopsy, or autopsy, no actual false-positives 
have occurred (20,24,39,49). 
TABLE 3 
Non-Neoplastic Causes of Positive Bone Scan 
Traumatic 
Fracture 
Slipped epiphysis 
Metabolic 
Paget's 
Renal osteodystrophy 
Hypertrophic pulmonary osteoarthropathy 
Gout 
Rickets 
Inflammatory 
Arthritis (any type) 
Osteomyelitis 
Tendinitis 
Miscellaneous 
Aseptic necrosis 
Osteitis pubis 
Hyperostosis frontalis interna 
Post-thoracotomy 
The Unified Radiologic Approach. Because of the 
already high and ever increasing cost of medical care, 
we need to reassess the manner in which bone scans 
and radiographs are utilized so that the patient may 
benefit from minimum waste and duplication of 
effort. To this end, we have developed a unified 
radiologic approach to the detection of skeletal 
metastases (51 ). An appropriate examination is 
"tailored" individually for each patient according to 
the scheme outlined in Figure 4 which is based on an 
extensive review of the literature as noted above. 
Because of the extensive experience in patients 
with primary neoplasms of breast, lung, and prostate, 
and also lymphoma, it is reasonable to perform the 
bone scan as the primary study in these patients. It 
has even been suggested that the bone scan com-
pletely replace the skeletal survey in the evaluation of 
all patients for skeletal metastases (52). This may 
shortly come to pass; however, reported experience 
with primary neoplasms other than those mentioned 
is not yet great enough. Therefore, we believe that in 
those patients it is still necessary to perform both 
complete examinations. It is much more efficient, 
nevertheless, to perform the scan as the initial study, 
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Fig 4-Scheme for radiologic examination of patients with suspected pone metastasis. 
even in the latter group. This is because the 
radionuclide bone scan, as generally performed, is an 
evaluation of the entire skeleton whereas the 
radiographic skeletal survey, as generally performed, 
covers only the axial skeleton. Thus, any sites outside 
the axial skeleton which may be positive on the scan 
can ~e radiographed at the time the skeletal survey i~ 
obtamed, thereby eliminating wasted time and effort. 
This approach is feasible only if false-negative , and to 
a lesser extent, false-positive bone scans occur infre-
quently . False-negative scans occur infrequently and 
Usually in specific circumstances as described above. 
To further minimize this possibility, however, we 
have incorporated into our approach a radiograph of 
the pelvis even if the scan is normal. As explained 
above, false-positive bone scans are, for practical 
purposes, almost nonexistent. 
The efficacy and practicability of the unified ap-
?roach was determined in a trial period during which 
1t was applied to all patients referred to the radiology 
department for either radionuclide bone scan or 
radiographic skeletal survey for the detection bf 
skeletal metastases . A comparison of the individually 
"tailored" examination actually performed with the 
examination (or examinations) requested by the 
clinical service revealed malutilization of these 
radiologic modalities; that is, superfluous, inadequate 
or inappropriate studies were requested in almost 
half the patients examined (51) . 
Conclusions. 
1. Technetium-99m-labeled phosphate com-
pounds are currently the agents of choice for radio-
nuclide bone scanning . 
2. Metastatic involvement of bone is most fre-
quently identified by a localized area of increased up-
take. Uncommon signs of skeletal metastasis are a 
localized area of decreased uptake and generalized 
symmetrically increased uptake with reduced renal 
excretion . 
3. Radionuclide bone scanning is much more 
sensitive than the radiographic skeletal survey for the 
detection of skeletal metastases. 
4. Since the findings on the bone scan are non-
specific, all abnormal areas should be radiographed 
to determine the nature of the abnormality. 
5. The incorporation of the radionuclide bone 
scan and the radiographic skeletal survey into a single 
unified examination for the detection of skeletal 
metastases, formulated and coordinated by the 
radiologist, is desirable, practicable, and efficacious. 
Table 1 and Table 2 reprinted with permission from 
Radiology, Vol. 11 7, No. I. 
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Figure 4 reprinted with permission of Radiology, Vol. 117, 
No. l. 
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Trauma is now a major medical problem. Ac-
cidental injuries constitute the fourth leading cause of 
death in the United States, and the primary cause of 
death below the age of 37. 
The costs of immediate medical and surgical 
care, prolonged hospitalization, and lost productivity 
amount to several billions of dollars annually. 
Nuclear medicine techniques have an important 
place in the evaluation of the injured patient. In 
general, they are rapid and noninvasive. They can 
provide functional as well as anatomic information. 
The sensitivity is often greater than that of routine 
radiographic procedures, particularly in the evalua-
tion of bone lesions. The accuracy of imaging in 
evaluating traumatic damage to the skull and ab-
dominal organs approaches or equals that of 
angiography. 
An awareness of the wide range of examinations 
available to the physician who must evaluate and 
treat the injured patient is necessary if these ex-
tremely useful techniques are to be utilized. 
The following discussion will describe 
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the radionuclide procedures used in diagnosis of 
trauma and their clinical usefulness. For review of the 
literature and extensive documentation of the studies 
and results explained below, the reader is referred to 
the articles listed at the conclusion of this discussion 
(l-4). Specific citations will not be made here, except 
for studies not included in these reviews. 
I. Central Nervous System Trauma. 
A. Brain Imaging: Radiographic examination of 
the skull provides minimal information in the pa-
tient with head trauma. The presence or absence of 
linear skull fracture has no demonstrable relationship 
to the presence of significant intracranial damage 
(5, 6). Contrast angiography is highly specific and 
provides high-resolution studies of the intracranial 
vascular tree and traumatic mass lesions. However, 
it is expensive and uncomfortable and has a signifi-
cant morbidity. 
Radionuclide studies are more revealing than 
plain films. They are also less expensive, less uncom-
fortable, and far less invasive than angiographic 
procedures and can provide useful information about 
intracranial blood flow and traumatic damage. 
I . Extracerebral hematomas. Subdural hema-
tomas are found in 55% to 70% of patients suc-
cumbing to head injuries. Epidural hematomas occur 
about one-fifth as frequently. The patient with an 
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acute collection may be too s.eriously injured to be 
studied, but imaging studies can be quite useful in the 
patient with a chronic subdural or, more rarely, 
chronic epidural hematoma. 
In subdural hematoma, caused by rupturing of 
cerebral veins passing through the subdural space en 
route to the venous sinuses, the blood first clots and 
may liquefy in two to four days. A fibrinous 
pseudomembrane forms during the next ten days, fol-
lowed by development of a true fibrous membrane by 
three to four weeks. 
The most popular radionuclide for evaluation 
of cerebral collections is 99mTc-pertechnetate. 
More recently, 9amTc-DTPA, -glucoheptonate, -di-
phosphonate, and -citrate have been successfully 
used and in selected cases may prove superior to 
pertechnetate (7, 8, 9). It is not certain whether the 
accumulation of nuclide in the subdural fluid or in 
the membrane accounts for the appearance of activity 
on the brain scan. Certainly, scans are more likely to 
be positive late in the course, when membranes are 
well-developed, than early, before they have formed. 
The typical appearance of an extracerebral 
hematoma is a "hot" crescent seen on anterior and 
posterior static views, with little or no abnormality 
on lateral view (Fig 1). The crescent appearance is not 
specific, and can be seen in many intra- and ex-
tracranial lesions, including scalp trauma, skull frac-
ture, craniotomy defect, unilateral Paget's disease, 
meningitis, cerebral contusion or hematoma, infarct, 
and tumor. False-positive crescents can be caused by 
rotation of the head. The intracerebral location of 
some of these conditions can often be determined on 
lateral views, where the circumscribed nature of the 
increased activity can be quite different from the 
diffuse increase seen in subdural hematoma. Of 
course, peripheral intracerebral lesions may be diffi-
cult to differentiate. Correlation with physical 
findings, radiography, and dynamic imaging (see 
below) is necessary in evaluating the crescent sign. 
Another, much less common, appearance of a 
subdural hematoma is the "rim sign," a curvilinear 
area of increased activity adjacent to an area of 
decreased activity. It is probably caused by displace-
ment and compression of normal brain by the ex-
tracerebral collection. 
The appearance of epidural hematomas is less 
extensively documented because fewer patients have 
been studied. The patterns appear to be the same as 
those of subdural hematoma. 
Extracranial lesions can often be ruled out or 
confirmed by performance of dynamic brain imaging 
(Fig 1). A bolus of 10 to 15 millicuries of the 
radionuclide is injected rapidly into a peripheral vein. 
The Oldendorf technique of arterial occlusion may be 
used, but is probably not neccessary for this purpose. 
A simple tourniquet and relatively quick injection of 
a high-activity, low-volume ( ~ 1 ml) bolus usually is 
adequate. The patient's head is positioned under the 
gamma camera before injection, usually in the 
anterior position unless a posterior site of injury in-
dicates the need for a posterior study. Images are ob-
tained every 2 to 3 seconds for 15 to 25 seconds. 
Static images in anterior, posterior, and both lateral 
positions are then obtained immediately and two to 
four hours later. 
The diagnostic accuracy or sensitivity of the 
brain scan ranges from approximately 50% during the 
first ten days after trauma to 90% thereafter. The 
results in children are somewhat less impressive, in 
Fig I-Right subdural hematoma. The initial 2 frames on top are 
from the early posterior radionuclide angiogram. Note peripheral 
avascular zone superiorly (arrows) . The static views performed 2 
hours later show a thickened right vascular rim on the sagittal pro-
jections associated with a diffuse increase in activity over the 
hemisphere on the right lateral view. Compare this latter finding 
with the normal left lateral view. 
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the range of 60% to 75%. Dynamic imaging has 
reportedly raised the diagnostic accuracy of early 
studies to nearly 100%, but in some series has been 
positive in only half of proven cases of subdural 
hematoma. The sensitivity of the examination is im-
proved by obtaining images several hours after injec-
tion and repeating equivocal studies after several 
days. This also decreases the problem of false-
positives because of soft tissue scalp trauma, which 
demonstrates rapidly diminishing activity over 
several days. 
A negative study does not rule out the presence 
of a small subdural collection. The resolving 
capabilities of cerebral angiography are un-
questionably higher and its sensitivity approaches 
100%. Radionuclide imaging should diagnose collec-
tions of more than I cm in diameter. It may be diffi-
cult to appreciate subdural collections by imaging 
when they are located in the posterior fossa, under 
the temporal lobe, or in other unusual locations. 
Bilateral small collections may be deceptive since 
the observer cannot compare one side to the other. 
This is a particular problem in children, in whom 
bilateral collections are more common than in adults. 
However, the striking thickness of the vascular rim 
can suggest the diagnosis (Fig 2). The study should 
not be called truly negative unless delayed views are 
obtained and are normal. The incidence of positive 
scans increases over one to four hours after injection, 
and equivocal studies can be definitely diagnostic if 
delayed imaging is performed. 
Fig 2-Bilateral subdural hematomas. This static scin-
tiphotographic study was performed 2 hours following injection. 
Thickening of both vascular rims on the sagittal projections is as-
sociated with a diffuse increase in uptake over both hemispheres on 
the lateral views. 
2. Intracerebral hematoma and contusion. Few 
cases of intracerebral hematoma have been reported, 
probably because the acute nature of the patient's 
condition often precludes radionuclide evaluation. 
However, the appearance of a well-defined area of in-
creased activity within the brain, on all projections, 
has been described. The appearance is in-
distinguishable from tumor, abscess, or infarct, and 
the study must be interpreted in context and 
sometimes repeated. Again, delayed imaging will lead 
to more positive diagnosis. The sensitivity of the 
study is about 65% to 75%. 
Contusion may present a similar appearance on 
imaging studies, but no definite mass can be seen 
when angiography is performed. The scan returns to 
normal over several weeks. More often, the scan in 
cases of contusion is normal. 
3. Radionuclide cisternography. This is a more 
difficult and invasive procedure than brain scanning, 
and because of the risk of aseptic meningitis, causes a 
higher morbidity. However, in certain instances it can 
reveal very useful information. A small volume con-
taining 0.5 to 1.0 millicuries of m1n-DTPA is in-
troduced directly into the subarachnoid space via 
lumbar or cisternal puncture. Sequential views in 
lateral and anterior positions over the spine and skull 
are necessary. 
The study can be used to detect CSF leaks from 
the spinal canal (I 0) (Fig 3) or skull. In the latter 
case, nasal pledgets can be left in place for later 
counting as an aid in detecting leaks through the 
frontal sinuses, cribriform plate, sphenoid sinus, and 
petrous bone. If proper techniques are employed, the 
accuracy of the procedure is quite high (>90% ). After 
a leak has been seen, rectilinear scanning may be per-
formed for more exact correlation with skull x-rays 
in determining the surgical approach . 
The syndrome of normal-pressure hydro-
cephalus can occur after traumatically induced sub-
arachnoid bleeding. The mechanism is presumed to 
be obstruction of usual CSF absorption pathways 
by adhesions. Abnormal CSF flow patterns can be 
detected by radionuclide cisternography. Serial imag-
ing at I, 6, 24, and 48 hours demonstrates filling of 
dilated ventricles at 24 hours without the normal ac-
tivity over the hemispheres, and ventricular stasis at 
48 hours. 
II. Liver and Spleen Injury. 
The liver is injured in 5% to 10% of patients 
suffering blunt abdominal trauma, and is the most 
commonly injured organ in penetrating abdominal 
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Fig 3-Spinal cerebrospinal fluid leak . The patient was a 50-year-
old man who developed right lower extremity weakness following a 
stab wound of the low back. Upper Left. Posterior Anger camera 
scintiphoto of head 4 hours after intrathecal Cl-C2 injection of 131 l-
Human Serum Albumin shows normal distribution of activity in 
basal cisterns. Upper Right. Posterior view of the dorsolumbar 
spine at 4 hours shows normal uniform distribution of activity. 
Lower Lefi. Posterior view of head at 24 hours shows normal 
progression of tracer over convexity . Lower righ1. Posterior view of 
lumbosacral spine at 24 hours shows oblique band of activity (ar-
rows) running between subarachnoid space and site of stab wound 
(hot spot marked by "Co source). Band represents CSF-cutaneous 
fistula. 
trauma. The spleen is ruptured or lacerated twice as 
often as the liver in blunt abdominal trauma. The 
mortality of liver damage is higher than that of the 
spleen, accounting for as many as 30% of the deaths 
occurring after closed abdominal injury. 
Clinical and laboratory- data are often non-
specific, as are plain films of the abdomen. 
Radionuclide imaging is as reliable as angiography 
(see below) and does not require arterial puncture or 
injection of large doses of hyperosmotic media. 
Examination is performed within a few minutes 
after injection of I to 3 millicuries of 99mTc-sulfur 
colloid. Anterior, posterior, and lateral views are ab-
solutely necessary. Oblique and angled views are 
often needed for full evaluation of the spleen (see 
below). Some investigators have found dynamic im-
aging useful, but its role is less vital than in skull, 
renal, and vascular injury. 
Laceration of a solid organ causes a linear or 
focal defect in the visualized activity (Figs 4, 5). A 
localized hematoma causes a round or wedge-shaped 
defect that, on appearance alone, can be in-
distinguishable from tumor, abscess, cyst, or infarct. 
A bipartite or accessory spleen may simulate transec-
tion, but this has not yet been a clinical problem in 
our experience. Subcapsular hematoma causes a flat-
tening of the border of the liver or spleen, and separa-
tion of the organ from the body wall or diaphragm, 
but the latter is difficult to discern on radionuclide 
imaging, and variations in normal organ position can 
be deceptive. Patchy or inhomqgeneous uptake may 
also be seen and, in the liver, .must be differentiated 
from cirrhosis. 
Fig 4-Liver laceration and hematoma in young male adult after 
motorcycle accident. A and B are anterior and right lateral ••mTc-
sulfur colloid liver scintiphotos, respectively , which show a large 
right lobe defect. In C, selective hepatic angiography shows pool-
ing of opaque material in a large cavity (arrows) which corresponds 
to the defect seen on scan. This represents pseudoaneurysm with 
hematoma formation. D and E are scintiphotos obtained 5 months 
after surgical repair . The tremendous regenerative ability of 
hepatic tissue is demonstrated. 
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No false-negative results have been reported in 
diagnosing hepatic injury. The incidence of false-
positive scans is quite low, on the order of 3% or less 
(Table 1 ). Because no clinically significant injury will 
apparently be missed, it is a suitable screening test for 
liver damage. Angiography can be reserved for 
equivocal cases or when precise anatomic definition is 
necessary for surgery. 
Spleen imaging has led to a correct diagnosis in 
about 90% of more than 200 cases reviewed (Table 2). 
In terms of clinically significant splenic damage, the 
accuracy of the procedure is even higher. 
lntraparenchymal extravasation or "puddling" as 
seen on angiography is not a criterion for surgery if it 
is the only demonstrable abnormality; such a case ac-
counts for one of the so-called "false-negative" cases 
reported. A proven subcapsular hematoma has been 
missed scintigraphically, since the expected flattening 
of the splenic border was not present. 
Attention to positioning of the detector head 
and knowledge of the relationships of the left hepatic 
Fig 5-Ruptured spleen in a 9-year-old boy after trauma. A. ••mTc-sulfur colloid scintiphotos show a large spleen with a wide lucent 
band through the midportion. B. Selective celiac angiogram also shows the wide defect seen in the splenogram . C. Longitudinally 
cut surgical specimen confirms the rupture through the midbody of the spleen. 
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TABLE 1 
Liver Imaging in Abdominal Trauma 
No. of True 
Study Patients Negative 
A 119 100 
B 19 16 
c 8 3 
D 16 15 
162 134 
lobe to the spleen can minimize the chance of false-
positive diagnosis of spleen injury. Angling and 
obliquing the detector allows visual separation of the 
spleen from the overlapping left hepatic lobe, which, 
in the straight posterior postion, may simulate a 
wedge-shaped defect in the spleen (see accompanying 
article on pitfalls and artifacts in this issue). Rib im-
pressions may also simulate lacerations, but can be 
suspected by the orientation of the defect and ruled 
out by obtaining views with a lead strip marker in 
place over the rib. 
With an unequivocally normal study, further ex-
amination of the spleen and liver is usually unneces-
sary. A critically ill patient with a definitely abnormal 
scan requires surgery. In cases of equivocal imaging 
findings or atypical history or physical examination, 
angiography may be necessary for further evaluation. 
This is particularly important when there is a pos-
sibility of subcapsular hematoma, which can lead to 
delayed rupture. However, despite the superior 
resolution of angiography, sizable lesions 'may be 
missed, possibly because it is difficult to obtain multi-
ple projections (Fig 6). 
Any patient with tra~ma to the left upper 
quadrant should be evaluated for possible kidney in-
jury in addition to splenic injury. 
False True False % 
Negative Positive Positive Correct 
0 17 2 98.3 
0 3 0 100 
0 5 0 100 
0 0 100 
0 26 2 98.7 
III. Genitourinary Tract Injury. 
Although penetrating wounds and iatrogenic 
damage such as renal biopsy and surgery account for 
a number of renal injuries, about 90% are the result of 
blunt abdominal trauma, predominantly automobile 
accidents. Severe renal injury is not so often an im-
mediate threat to life, as is severe hepatic or splenic 
injury, except in cases of penetrating injury. 
However, the late sequelae of renal parenchymal loss 
can be serious and include hydronephrosis, calcified 
hematoma, calculi, pseudocyst, and scarring and 
arterial injury leading to hypertension. 
Minor renal damage occurs in the majority 
(65%) of instances of renal injury, according to the 
widely used classification of Hodges, et al. Contusion 
is the commonest minor injury. Major disruption of 
the parenchymi\, with rupture of the capsule, exten-
sion into the collecting system, and/ or segmental 
vascular occlusion accounts for 30% of renal injuries. 
Critical injury, with disruption of the renal hilus with 
its major vessels, is rare. 
Although the intravenous urogrijm, preferably 
with a high dose of contrast media, is usually the first 
examination performed in the patient with suspected 
renal injury, studies of diagnostic quality cannot 
always be obtained. A rapidly running intravenous 
TABLE 2 
Spleen Imaging in Abdominal Trauma 
No. of True False True False % 
Study Patients Negative Negative Positive Positive Correct 
A 119 91 0 24 4 96.6 
B 19 14 0 0 100 
c 32 19 II 0 93.7 
D 16 2 I 12 I 87.5* 
E 16 9 0 7 0 100 
202 135 2 59 5 96.0 
* False-positive can be avoided. False-negative was insignificant puddling. (see text). 
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Fig 6-Minor nonsurgical spleen injury in 33-year-old man after stab wound. A. A ••mTc-colloid study at the time of injury (top 
row) shows a foca l area of decreased uptake along the posteromedial border. Angiogram performed at this time is shown in 6B. Repeat 
radionuclide study two months later (bottom row) in the same left lateral and posterior veiws show disappearance of the abnormality. 
B. Selective splenic angiogram (late phase) at time of injury in anteroposterior position fails to show the abnormality seen on the 
scintigraphic study. Apparent lucencies over the lower portion of the spleen represent bowel gas. 
line can cause significant dilution of the contrast 
media, and overlying gas and feces can interfere with 
interpretation. 
Radionuclide examination, in dynamic and 
static modes, provides information about the 
vascular supply of the kidney, parenchymal integrity, 
and excretory function, combining some aspects of 
both urography and angiography. For dynamic im-
aging, a 10 to 15 millicurie bolus of one of the 99mTc-
labeled renal agents is injected rapidly into a 
peripheral vein, preferably the antecubital. Beginning 
6 seconds after injection, 2- to 3-second exposures are 
obtained until approximately 30 seconds after injec-
tion. If rapidly filtered 99mTc-Sn-DTPA is used, im-
mediate and serial scintiphotos over a 30-minute 
period are made. If one of the agents that is fixed to 
the tubules is used (99mTc-iron-ascorbate, 99mTc-glu-
coheptonate, or 99mTc-DMSA), one- and two-hour 
static delayed images are obtained. The 99mTc-
labeled compounds have largely replaced 197Hg-
chlormerodrin as cortical imaging agents because of 
more favorable physical characteristics. 
The posterior view is used for renal imaging. A 
diverging collimator is helpful for imaging large adult 
patients, in order to image both kidneys 
simultaneously in one field, but is not necessary in the 
average adult or in children. Delayed imaging of the 
bladder is done in the anterior position. 
The commonest renal injury, cortical contusion, 
may cause early diminished blood flow on dynamic 
imaging and persistent defect or sometimes 
generalized decreased activity on delayed imaging 
(Fig 7). A persistent focal defect is difficult or impos-
sible to differentiate from infarct or hematoma. In-
farct will remain as a defect on follow-up imaging, 
while contusion may resolve over two to four weeks 
(Fig 7). Hematoma may resolve or progress to 
infarct. 
If no activity is seen to reach the kidney on 
dynamic and subsequent static imaging, renal arterial 
occlusion or other disruption of the renal hilus must 
be suspected. This is an indication for immediate sur-
gical intervention to attempt salvage of renal func-
tion. Arteriovenous fistula caused by trauma or renal 
biopsy is apparent on dynamic imaging as an area of 
early intense activity and rapid washout. 
A fragment of lacerated or fractured kidney may 
demonstrate diminished perfusion early and in-
creased activity late, but the associated linear defect 
dividing the kidney into more than one fragment 
often distinguishes this pattern from contusion. 
Extravasation of activity can be seen in 
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Infarct 2 mos. later 
Fig 7-Value of serial radionucli<;le examination in differentiating between renal contusion and 
infarction. Posterior "'Hg-chlormerodrin scintigraphy following blunt trauma (lop row) shows 
diminished activity in the medial portion and lower half of the right kidney. Repeat study 3 
weeks later demonstrates considerable improvement in the appearance of this contused kidney. 
Sequential radiochlormerodrin study in another patient with blunt trauma (bottom row) shows 
a band of decreased activity through the midportion of the left kidney , which remains relati vely 
unchanged after 2 months. Subsequent studies showed no change over 4 additional months . 
An area of contused parenchyma seen below the infarct shows marked improvement on the 
2-month study. This patient is being followed closely for the possible development of hy-
pertension. 
parenchymal and pelvocalyceal tears (Fig 8), and the 
chances of demonstrating it are increased if early and 
late scintiphotos are obtained. Extrarenal c.ollections 
such as retroperitoneal hematoma, urinoma, and 
lymphocele (following renal transplant) cause voids 
in the visualized background activity and distort the 
urinary tract structures by their mass. 
When total nonfunction of a kidney is seen on 
urography, and 0 11 dynamic and static renal imaging 
with a cortical agent, radiohippuran studies may be 
useful in determining the presence of functioning 
renal tissue. Hippuran I-131 is also useful in measur-
ing renal function in cases where post-traumatic com-
promise is suspected and in following renal function 
in these cases. 
Radionuclide examination compares favorably 
to angiography in detection and delineation of renal 
injury. It is reportedly superior to aortography in 
diagnosing mild to moderate renal injury such as con-
tusion. Selective catheterization increases the 
diagnostic accuracy of contrast angiography, but also 
increases the morbidity of the procedure. Radionu-
clide imaging often is superior to urography in de-
fining the extent of damage, and sometimes dem-
onstrates injury that would be unsuspected from 
urography alone. The development of ultrasonography 
provides a method to determine the presence or ab-
sence of a kidney that shows no function on urog-
raphy . This noninvasive technique, with the virtually 
noninvasive radionuclide techniques described, can 
decrease the instances when angiography is required 
for renal evaluation after trauma. 
IV. Peripheral Vascular Injury. 
Dynamic imaging can be useful in evaluation of 
acute vascular injury and its sequelae. The basic prin-
ciple, as with other dynamic imaging procedures 
described above, is rapid introduction of high-
specific-activity radionuclide in a small volume (less 
than 1 ml). Usually 99mTc-pertechnetate is used. 
However, when it is desirable to obtain multiple 
views of an injured area, the first injection may be 
made with a substance which is removed by an organ 
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Fig 8-Renal laceration. Renal scintiphoto performed one minute 
after injection of 99mTc-iron-ascorbate shows a "cold" area at the 
lower pole of the right kidney. A follow-up study one hour later 
clearly shows the laceration at the lower tip of the kidney with ac-
tivity leaking into the area of hematoma. 
during one pass through the circulation, for example, 
9~mTc-S-colloid by the liver. The background radioac-
tivity is then reduced, and the second injection can be 
made with pertechnetate. Scintiphotos are obtained 
every 2 to 3 seconds for 15 to 25 seconds, and a static 
image of 300,000 counts is obtained at conclusion of 
the dynamic phase. A data processor allowing subse-
quent playback and analysis can be helpful in this as 
in other dynamic examinations, but is not absolutely 
necessary for clinical usefulness. 
Extravasation into a paravascular hematoma 
can be seen early as an irregular collection of activity 
adjacent to a vessel. The activity may increase in in-
tensity in static images. A well-defined circular area 
of early increased activity in the vicinity of a major 
vessel suggests pseudoaneurysm, not an uncommon 
finding several weeks after trauma (Fig 9). 
Traumatic arteriovenous fistula, as described in the 
section on urinary tract injury, presents a picture of 
early activity in the fistula and draining vein, with 
early washout. Iatrogenic arteriovenous shunts for 
dialysis can be studied in the same way. Traumatic 
occlusion of an artery will cause deficient activity in 
the area of its supply. 
The venous system can also be visualized, if in-
jection is made into the vein distal to the site of in-
jury. Technetium-99m-MAA or microspheres are 
used for venous studies. Collateral circulation and ac-
tual sites of thrombosis or other occlusion can be 
demonstrated. 
V. Skeletal Trauma. 
The extensive use of radionuclide imaging in 
benign bone disease is a relatively new phenomenon, 
facilitated by the development of 99mTc-la-
beled phosphate complexes (polyphosphate, 
diphosphonate, and pyrophosphate). These com-
pounds are relatively inexpensive, widely available, 
have convenient physical characteristics, and yield a 
low patient radiation dose, thus overcoming most of 
the objectionable qualities of previously used com-
pounds. The body of literature on radionuclide imag-
ing findings in trauma is small, much of the ex-
perience having been gained incidentally in study of 
malignant disease with 85Sr, s7msr, and 18F. 
With the 99mTc agents, bone imaging is per-
formed two to four hours after intravenous adminis-
tration of 10 millicuries of the phosphate complex in 
adults, or appropriately smaller doses in children. 
Total body scanning with a high-speed, dual-probe 
scanner or camera with moving table or detector ac-
cessories is desirable for potentially generalized 
problems. Localized studies are usually performed on 
the gamma camera, which yields high-resolution im-
ages with these compounds. 
A useful area of examination in acute trauma is 
in detection of a bone bruise or fracture that may be 
difficult to detect radiographically, such as in the ribs, 
or in the vertebral column (Fig JO). In children, frac-
tures may be difficult to detect because of incomplete 
ossification of the skeleton. Such sites of trauma can 
be appreciated on imaging studies, which depend on 
the hyperemia associated with reaction to trauma, 
rather than on mineral density of the bone. The pat-
tern of injury in the appropriate context may suggest 
child abuse at a time when radiography is equivocal. 
After two to three days, both actual fractures and 
periosteal or superficial bone injury without fracture 
may be "hot" despite negative radiographs (Fig 10). 
The activity decreases in intensity over a period of 
several months to years. The pattern of activity in-
volving multiple bones can help distinguish trauma 
from osteomyelitis, which also can cause intensely 
"hot" uptake, but is not commonly multifocal. 
Imaging is particularly valuable in following the 
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Fig 9-Pseudoaneurysm of left peroneal artery after stab wound·. A .Angiogram demonstrates the presence of a large pseudoaneurysm with 
arteriovenous shunting in the distribution of the left peroneal artery. B. Serial scintiphotos performed over the knee area following a bolus 
injection of••mTc-pertechnetate reveal a large collection of activity which remains long after the vessels empty. A one-minute static cumula-
tive image shown at the lower right contrasts with the background vascular activity in the muscle mass of the leg. 
healing process after accidental fracture or iatrogenic 
trauma such as osteotomy or bone graft. Activity 
bridging the gap in the bone will appear before 
radiographically visible bony bridging. Failure of this 
to occur predicts nonunion or pseudarthrosis forma-
tion. 
The possibility of aseptic necrosis of the femoral 
head following subcapital fracture may be accurately 
predicted by demonstrating diminished activity early, 
with failure of activity to return after several weeks. 
Revascularization of an area of aseptic necrosis 
causes increased activity (11). 
Artifacts of increased activity may be seen in soft 
tissue injury such as incisions or organizing 
hematomas, as well as in ectopic bone formation, fol-
lowing trauma and other insults. It is common to see 
diffusely increased activity over the upper hemithorax 
after mastectomy. Although this may be partly due to 
decreased photon attenuation by the smaller mass of 
overlying soft tissue, the absence of improved rib 
definition suggests that it is actually soft tissue activ-
ity. It must be differentiated from tumor recurrence, 
which can cause localized increased act1v1ty, and 
from malignant pleural effusion. The latter is gen-
erally more diffuse and is present on both posterior 
and anterior views. 
Radiation injury to the bone, as to other organs, 
ultimately causes a sharply defined field of 
diminished uptake, although in the early post-
irradiation period, activity rriay be greater than nor-
mal. 
The 99mTc-phosphates are excreted by the 
kidney. Therefore, urine contamination must be 
avoided, especially in bone imaging of the pelvis and 
lower extremities, where it is likely to occur in the 
severely ill patient. The bladder should be empty in 
pelvic studies to avoid obscuring information. 
VI. Chest Injury. 
The methods of evaluating vascular and bone in-
jury have already been described. Imaging has been 
used in evaluation of hemothorax and _pulmonary 
contusion, but these studies do not actually add to 
the diagnostic capabilities of conventional radi-
ography. 
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A . B. 
Fig IO-Multiple spinal fractures seen on scintiphoto with only one fracture demonstrable on x-ray. The patient was a fireman who 
leaped out of a window landing on his feet. A. Posterior "mTc-pyrophosphate bone scintiphoto 4 days after injury shows 4 active lumbar 
vertebral bodies. B. Lateral lumbar spine x-ray shows disruption of L3 superior vertebral plate (arrow) . Multiple views failed to show any 
other evidence of fracture. 
Traumatic hemopericardium, like other pericar-
dia! fluid collections, can be diagnosed by 
demonstrating a clear "halo" around the heart, 
separating it from lung and liver activity, during 
dynamic and static studies after administration of I 0 
to 15 millicuries of 99mTc-pertechnetate. 
Fat embolism and "shock lung" cause multiple 
perfusion defects or diffuse inhomogeneity of ac-
tivity on routine lung imaging with 99mTc-labeled 
macroaggregates of albumin or microspheres. 
Although the imaging findings are indistinguishable 
from pulmonary emboli of other etiologies, in the ap-
propriate clinical setting the study may confirm the 
diagnosis. 
Inhalation studies with 133Xe may help to 
diagnose burns of the respiratory tract. Areas of 
delayed filling and slow washout suggest obstruction 
to air flow. This may be seen in chronic obstructive 
lung disease, foreign body, or bronchiectasis, but in 
the appropriate setting can confirm a suspicion of 
tracheobronchial injury or edema related to smoke or 
fume inhalation. If 133Xe in saline is injected in-
travenously, perfusion defects can be documented, 
and subsequent rebreathing permits evaluation of 
ventilation patterns. 
Conclusion. Radionuclide imaging provides 
useful functional and anatomic information about 
many organ systems, especially when dynamic and 
static phas.es are utilized. In any but the most acute 
patient in need of immediate lifesaving therapy and 
direct surgical intervention, these studies might well 
be considered a routine part of the evaluation. In 
many cases, invasive procedures such as angi-
ography, myelography, and bronchography may be 
avoided, or at least limited in time and extent. Ac-
ceptably low radiation doses make multiple and 
follow-up studies reasonable. 
By facilitating early treatment of traumatic in-
jury in many cases, and by eliminating expensive and 
complicated procedures in others, the more 
widespread utilization of these techniques can help to 
decrease the tremendous human and economic costs 
of trauma. 
Table I and T able 2 are adapted from Gilday and Alderson, 
Seminars in Nuclear Medicine (4:357-370, 1974). 
Figures 3 and 4 are reprinted from the Journal of Nuclear Medicine, 
Vol. 14, No. 6, and Vol. 10, No. 10, respectively, with permission 
o f publisher. 
Figures 5 and 6 a re reprinted from Radiology (1 !0:419-425, 1974) 
with permission of authors and publisher. 
Figures 7 and 8 are reprinted from Seminars in Nuclear Medicine 
(4:117-132, 1974; 4:37 1-393, 1974, respectively) by permission of 
Grune & Stratton. 
Figure 9 is reprinted from Radiology (109:623-628, 1973) with 
permission of authors and publisher. 
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Radioimmunologic Methods for Diagnosis of 
Malignant Diseases 
PAUL B. HOFFER, M.D. 
Professor of Radiology and Director, Section of Nuclear Medicine, University of California Medical Center, San 
Francisco, California 
The recent availability of the carcinoembryonic 
antigen (CEA) assay has stimulated great clinical in-
terest in tumor antigens. Carcinoembryonic antigen 
is not the only specific or tumor-associated antigen 
currently identified . There are a number of other 
tumor antigens which have been isolated, some of 
which are related to CEA and some of which are 
totally different. There is, for example, a nonspecific 
cross-reacting antigen (NCA) which has been discov-
ered in certain preparations which were considered 
originally to be CEA. Nonspecific cross-reacting 
antigen is a beta globulin (25% carbohydrate) which 
cross-reacts with antibodies to CEA and may be 
the nonspecific background element that causes the 
CEA titer to be elevated in certain nonmalignant 
diseases. There is also a membrane-associated, low 
molecular weight tissular autoantigen (MT A) which 
has been recently identified. However, this material 
is not antigenetically related to CEA or NCA. 
Carcinoembryonic antigen is an antigenetic 
glycoprotein. The antibody-active site of this antigen 
is actually in the glucose portion of the molecule 
rather than the protein portion. Carcinoembryonic 
antigen has a relatively high molecular weight 
(200,000) and is soluble in perchloric acid. The per-
chloric acid solubility of CEA has greatly facilitated 
extraction of the antigen from tumor tissue and is 
also responsible for the relative convenience of the 
current method of performing the radioimmuno-
assay for detection of this antigen. 
Carcinoembryonic antigen is present in the 
This is an edited transcription of a lecture presented by Dr. 
Hoffer at the Postgraduate Course in Nuclear Medicine, February 
27, 1975, in Williamsburg, Virginia. 
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glycocalyx of malignant gastrointestinal cells and is 
also present in fetal gastrointestinal tissues during the 
first and second trimesters of fetal life. Gold and 
Freedman discovered and isolated this material in 
1965 (!). A radioimmunoassay for its detection was 
developed soon after (2). Initial results with this assay 
indicated that elevated blood CEA level was a specific 
test for adenocarcinoma of the colon, although oc-
casional patients with pancreatic carcinoma also had 
elevated titers. However, more extensive clinical 
studies indicate that circulating CEA is not only pre-
sent in colonic and pancreatic malignancies but in 
other malignancies as well, as noted by H. J. Hansen, 
MD (oral communication, April, 1973). Unfor-
tunately, CEA is also present in certain nonmalignant 
disorders and some normal patients. the common 
denominator in most cases of elevated CEA level as-
sociated with bowel disease is rapid cellular prolifera-
tion with disruption of the basement membrane. The 
disruption of the basement membrane is important 
because the antigen must leak into the circulation in 
order to be detected. The cellular proliferation may 
be responsible for the cell surface exposure of certain 
primitive antigens that are not normally found in 
adult human tissues . The upper limit of normal for 
the currently available CEA assay is approximately 
2.5 ng/ ml. However, a finite percentage of normal in-
dividuals will have CEA levels above this value. 
Three percent of healthy, young nonsmoking 
volunteers and 19% of smokers have CEA levels over 
2.5 ng/ ml. There is some question as to whether the 
smokers who do have elevated titers are not in fact 
candidates for developing carcinoma of the lung, 
although the evidence for this is currently speculative. 
Former smokers have a fairly significant CEA titer 
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elevation. Thirty percent of patients with nonmalig-
nant disease may have a titer above 2.5 ng/ml, and 
10% of these patients have a titer above 5 ng/ml. 
However, the assay shows more frequent and more 
marked elevation of the antigen titer in patients with 
malignancy, especially colorectal carcinomas. Eighty 
percent of patients with colorectal carcinoma have a 
titer greater than 2.5 ng/ml. Fifty percent have a titer 
above 5 ng/ml. Other tumors such as lung carcinoma 
are also associated with a high incidence of elevated 
titer. 
An early criticism of the CEA assay was the high 
incidence of false-negative results in patients with 
early-stage colonic carcinomas. The five-year survival 
statistics for treated patients with Duke's stage A 
colonic carcinoma is almost 100%. In the stage B 
group, the survival is approximately 50% to 60%, and 
in the stage C group (those patients in whom the 
tumor has gone through the serosa and actually 
metastasized to local nodes), the survival drops to 
only about 25% at five years. Ideally, we would prefer 
an assay that would detect 100% of patients with 
colonic carcinoma, Duke's stage A (assuming that 
most of these tumors do go through a progression 
from stages A to C). However, using the current CEA 
assay, only 20% of patients with stage A lesions will 
have an elevated titer. In other words, 80% of the 
patients with this type of lesion will have a normal 
CEA titer. About 40% to 50% of patients with stage B 
lesions will have positive titers . It is only when the le-
sion actually breaks through the serosa and is involv-
ing local nodes that the probability of an elevated 
CEA titer approaches 90% to 100%. Therefore, the 
current CEA immunoassay cannot be used alone as a 
cancer-screening study. Its value in screening 
patients, however, should not be totally discounted 
since there is a significant five-year survival in treated 
patients even in the stage B and C categories. 
Doctor William McCartney, Mrs. Erika Lawrence, 
and I performed a study at the University of Chicago, 
comparing the relative value of the CEA titer to the 
conventional colon examination for the diagnosis of 
carcinoma of the colon (3). The study included almost 
1,000 patients who were referred for radiologic colon 
examination . Carcinoembryonic antigen titer above 3 
ng/ ml (a level we arbitrarily selected to divide the 
normal from abnormal groups) was detected in 15% 
of patients subsequently diagnosed as normal, or 
having inactive inflammatory bowel disease. There 
was a 30% incidence of elevated titers in patients who 
had cirrhosis and noncolonic malignancies. Less than 
10% of the patients with benign colonic polyps in this 
series had significant titer elevation. 
By comparison, the conventional radiologic colon 
examination was positive, that is, showed evidence 
for malignancy in only 10 out of 850 patients who 
were subsequently established not to have colonic 
malignancy. The colon examination was, therefore, 
much more specific for excluding the diagnosis of car-
cinoma of the colon in patients subsequently proven 
not to have colonic maiignancy. 
Forty-eight of the patients in this series were subse-
quently proven to have carcinoma of the colon, first 
diagnosed at the time of the study. The CEA titer was 
normal in 16 of these patients and was abnormal in 
only 67%, whereas the conventional radiologic colon 
examination was abnormal in 90% of these patients. 
The radiologic colon examination was, therefore, 
clearly superior to the CEA test for detection of new 
carcinomas of the colon. However, there were three 
patients with carcinoma of the colon in this study in 
whom the radiologic colon examination was original-
ly considered to be normal or show signs representing 
benign disease, who did have elevated CEA titers. 
The CEA titer was potentially helpf~l in these cases 
in raising the suspicion of colonic carcinoma. If the 
results of the two tests are combined, the accuracy of 
the diagnosis is 96%, which represents some improve-
ment over the radiologic colon examination alone. 
In active ulcerative colitis, the CEA level is fre-
quently elevated and the level itself is not a useful clue 
to detect early development of malignancy. The 
patients with quiescent bowel disease usually have 
· normal titers. In a patient with quiescent bowel dis-
ease, a rising CEA titer should be treated with great 
suspicion for neoplasm. 
Although the radiologic colon examination is 
clearly superior for the initial diagnosis of colonic 
malignancy, the CEA titer is equally superior for the 
diagnosis of recurrence of colonic carcinoma. In our 
studies of patients with recurrent colonic carcinoma, 
only 2 of 15 patients with recurrence had a normal 
CEA titer. The barium enema indicated recurrence in 
only 3 of these 15 patients. The barium enema did 
detect the two cases of recurrence with normal CEA 
titers . Frequently, the recurrence of colonic car-
cinoma is not in the area of the primary tumor but 
rather in the liver or elsewhere in the body. It is also 
very difficult to distinguish postoperative changes in 
the bowel from early recurrence of tumor on a con-
ventional radiologic colon examination. These fac-
tors probably account for the poor detection rate of 
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recurrence seen with the conventional radiologic 
colon examination. 
In summary, the CEA titer is not as sensitive as the 
radiologic colon examination for the diagnosis of 
primary carcinoma, but it is very useful in following 
patients for recurrent carcinoma. 
Another area of potential use for the CEA 
radioimmunoassay is in the detection of metastatic 
malignancy of noncolonic origin. The test is ex-
tremely useful when interpreted in conjunction with 
other tests for metastatic disease. Doctor William 
McCartney, Erika Lawrence, and I studied 368 
patients who had both liver scans and CEA im-
munoassay ( 4). The liver scan is a useful test for the 
detection of hepatic metastasis for many primary 
malignancies; however, it has a 30% incidence of false-
negative results and a 10% to 20% incidence of false-
positive results. The false-positive cases are primarily 
patients with other disorders such as cirrhosis, who 
show lesions on the liver scan which closely mimic 
metastatic tumor. In this study, we chose a level of 9 
ng/ml as a dividing line between a positive result for 
metastatic tumor and negative evidence for 
metastatic tumor. It should be noted that this level is 
considerably higher than the level usually selected for 
detecting carcinoma of the colon . 
Neither the liver scan nor the CEA assay was 
perfect in detecting hepatic metastasis. However, 
when the results of both tests were positive, the 
probability that the patient had metastasis was 
almost 100%, and when both tests were negative, the 
probability of hepatic metastasis dropped to I%. If 
the liver scan only was positive, the probability of 
metastasis dropped to 60%, and if the CEA titer only 
was positive, that is, above 9 ng/ ml, the probability 
of hepatic metastasis was only 30%. These results sug-
gest an important role of the CEA titer in evaluating 
the patiepts with many types of tumors other than 
colonic malignancy. 
The continuing clinical use of the CEA titer will 
undoubtedly reveal many other situations in which 
the study is valuable. It is certainly not a diagnostic 
panacea, and the results must be interpreted with 
considerable caution. However, I believe we can look 
forward to an era of continued expansion in this type 
of tumor radioimmun oassay. More specific assays for 
colonic tumor are being developed and will un-
doubtedly become available in the future. I am equal-
ly confident that similar assay techniques will be 
developed for other types of malignancies. 
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Pitfalls and Artifacts in Nuclear Imaging Studies 
LEONARD M. FREEMAN, M.D. 
Associate Professor of Radiology and Co-director of the Division of Nuclear Medicine, Albert Einstein College oj 
Medicine , Bronx, New York 
In interpreting scintillation images, one often is 
confronted with a variety of deviations from the 
typically normal study that need not represent defi-
nite pathology. Apart from normal anatomic variants 
in the position, shape, or configuration of an organ, 
one must also be prepared to appreciate alterations 
due to the radiodiagnostic ageni employed and aber-
rations caused by faulty or improperly used instru-
ments. Additionally, physiologic and/ or functional 
changes associated .with specific organ studies have 
provided a major source of error in routine image in-
terpretation. It is the purpose of this article to ac-
quaint (or reacquaint, as the case may be) the reader 
with many of these problems so that they may easily 
recognize them and, one hopes, improve their overall 
interpretive abilities . 
The discussion will follow the lines of general 
considerations relating to instrumentation and 
radiopharmaceuticals followed by specific organ con-
siderations. In this type of review, some intentional as 
well as some unintentional omissions may appear . 
The author hopes that most of the common sources 
of error have been included. Undoubtedly, soine 
readers may think of other problems that they may 
personally have been confronted with. 
I. Instrumentation. Problems related to instru-
mentation may be related to malfunction of the 
equipment oi: faulty technique. 
A. Ma/function: 
1. Lack of field uniformity. In using scintilla-
tion cameras, one must have a relatively 
homogeneous response to gamma photons over the 
From the Division of Nuclear Medicine, Department of 
Radiology, Albert Einstein College of Medicine, Bronx, New 
York, and presented by Dr. Freeman at the Postgraduate Course 
on Nuclear Medicine, February 28, 1975, Williamsburg, Virginia. 
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entire crystal surface . A uriiform crystal with 
properly balanced, normally functioning phototubes 
is a prime requisite to proper image interpretation. 
The response from different portions of the same 
crystal may vary from one another by as much as 20% 
to 30%. Computer programs have been written to 
correct this problem. Since most individuals do not 
have this facility, a simple field flood each morning 
using a sheet source or separate Cobalt-57 sources, 
with the collimator off, should, at least, help one ap-
preciate what portions of the camera crystal are giv-
ing an inhomogeneous response. If the picture is par-
ticularly poor, the instrument should not be used and 
the manufacturer's service department should be con-
sulted . 
2. Faulty spectrometer. An inability to properly 
peak over the appropriate gamma photons of a 
radionuclide is a flaw that obviously would prevent 
one from obtaining a good image. Using the spectral 
bands available on the Anger scintillation camera, 
one should be able to appropriately "peak in" ori the 
desired energy range. Using rectilinear scanners, one 
should be able to obtain maximal count response if 
the pulse height analyzer window is properly 
positioned around the peak gamma photon energy. 
3. Defects in the electronic circuitry (pre-
amplifier, and other equipment) or display system 
(cathode ray tube, and other equipment). 
B. Technique: 
Certain human errors also must be considered in 
operating any electronic instrument. 
1. Improper calibration. Even though an instru-
ment may be functionally sound, electronic "drifts" 
due to fluctuations in input voltage and other similar 
factors may cause changes in the settings required to 
obtain optimal response at a particular energy 
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range. Frequent calibration checks by the tech-
nologist are needed to correct this difficulty. 
2. Faulty settings for contrast enhancement, den-
sity, or time contrast. These are problems more often 
associated with rectilinear scanners than stationary 
cameras primarily related to the fact that there are 
many more dials for the technologist to manipulate 
on the former. Contrast enhancement settings deal 
with the range of gray scale over which the counts 
from the area being studied are spread. Too narrow a 
range will create a very contrasted image which may 
give a false impression of an abnormal area. The ex-
perienced interpreter should recognize this im-
mediately. On the other hand, too little contrast 
enhancement may, in some instances, mask abnor-
malities. Similar situations may exist for density set-
tings which deal with duration of light flash and time 
constant settings which deal with length of sampling 
time for a particular event or position of the detector. 
3. Information (count) density. This refers to the 
amount of information one obtains in a unit area to 
create an interpretable rectilinear scan image. Nowa-
days, we strive for count densities of 600 to 2000 
counts per square centimeter. A simple formula used 
to achieve this factor is as follows: 
Maximal Count Rate 
Count Density = . · . 
Scan speed X Line spacing 
if one keeps the line spacing constant at 0.3 to 
0.4 cm, a simple direct relationship between count 
rate and usable speed is obtained. A simple technique 
chart can be developed for the instrument operator 
relating these factors to obtain a desired count den-
sity. 
4. Improper collimator. The use of an improper 
collimator can destroy an otherwise good study; for 
example, a low energy 140 kev collimator cannot be 
used for an 1311-1-iippuran renal study since the 364 
kev gamma photon of 1311 will penetrate the col-
limator's lead septa causing considerable scatter 
radiation resulting in loss of resolution and image 
degradation. 
Most of these aforementioned problems as weli 
as several others are discussed at some length in a re-
cent article by Harris (1 ). 
II. Radfopharmaceuticals. Potential problems 
with radiodiagnostic agents are encountered in each 
individual organ-imaging area, and specific situations 
will be primarily considered as each organ system is 
discussed. These difficulties relate to both the 
preparation of these different materials as well as cer-
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tain technical factors . Some general problems such as 
low specific activity or concentration, poor com-
pound labeling, presence of radionuclide impurities, 
infiltration of the injected dose, and miscalculation of 
the dose are applicable to all of the subsequently dis-
cussed clinical areas. 
III. Brain Imaging. In brain scintigraphy, diffi-
culties with both the radionuclide angiogram 
(dynamic study) and blood-brain barrier study (static 
study) may be encountered. 
A. Radionuclide angiogram. 
1. Jugular-venous reflux. A sudden Valsalva 
maneuver by the patient during a rapid intravenous 
bolus injection of a radiopharmaceutical can cause 
the tracer to reflux up the jugular vein instead of 
proceeding on its normal pathway to the heart (2). 
This is recognizable as a band of activity entering the 
head (sometimes into the transverse sinuses) well 
before normal circulation time would fill the carotid 
arterial tree (Fig I). It should not be misinterpreted as 
asymmetric arterial flow. A second factor that may 
cause such venous reflux is venous obstruction in the 
upper thorax, for example, superior vena caval 
obstruction, in which case reflux up the jugular repre-
sents the path of least resistance. 
2. Expected asymmetries in elderly patients. Fif-
Fig 1-Jugulo-venous reflux . A bolus of ••mTc-pertechnetate ad-
ministered through a left antecubital vein is seen to reflux up left 
jugular vein on 0-4-second scintiphoto. At 4-7 seconds, it has 
refluxed back into transverse sinus and down right jugular vein. At 
7-10 seconds, normal arterial flow to head is visualized. 
Diminished right cerebral perfusion signifies presence of a right 
cerebrovascular accident. 
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teen to 20% of patients over the age of sixty can be ex-
pected to have asymmetric arterial flow solely on the 
basis of normal arteriosclerotic change (3). No focal 
neurologic findings are demonstrable in this group of 
patients. 
3. Bilateral carotid stenosis. The author has en-
countered two situations where bilateral carotid 
artery stenosis has caused long delays in the cerebral 
appearance of an antecubital intravenous injection of 
99mTc-pertechnetate. Since an infiltrated injection 
could cause the same finding, one should be aware of 
this particular disease entity when encountering such 
a study. 
4. luxury perfusion in cerebrovascular accidents. 
On occasion, increased rather than decreased flow 
may be observed in a patient with an acute 
cerebrovascular accident (3). This is believed due to 
regional hyperemia and vasodilatation around the in-
farcted area. This phenomenon generally subsides 
over a two- to four-week period. Such increased per-
fusion should not be misinterpreted as a vascular 
malformation or neoplasm, 
B. Static brain studies: 
I. Choroid plexus activity. The normal biologic 
localization of radiopertechnetate in the choroid 
plexus has been greatly emphasized (4, 5). Prior com-
petitive blocking with potassium perchlorate has 
greatly minimized this problem. If continuing diffi-
culty exists, even after perchlorate block, a repeat 
study with a different tracer such as 99mTc-DTPA 
may be obtained. The question of whether or not 
perchlorate premedication will prevent pertechnetate 
uptake in an abnormal choroid plexus, for example, 
papilloma or meningioma, has aroused some interest. 
In general, most reports indicate that it will not in-
terfere with uptake in choroid plexus lesions. This 
was also the case in this author's large series of one 
case (Fig 2). 
2. Saliva artifacts. Since pertechnetate is ac-
tively picked up by the salivary glands and excreted 
into the mouth, saliva artifacts must be watched for. 
This is generally encountered in comatose or 
semicomatose patients and children where drooling 
may allow saliva to collect on different parts of the 
head and neck (Fig 2). Repeat studies after cleansing 
of the area should resolve the problem. 
3. Prosthesis-metal plate, glass eye, and other 
artificial parts. The relatively low gamma photon of 
99mTc is easily attenuated by such foreign objects. The 
old standbys of physical examination and plain skull 
radiographs should clarify any suspicions in this area. 
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Fig 2-Uptake in choroid plexus papilloma in a child unaffected 
by potassium perchlorate premedication . Right lateral scintiphoto 
at top shows intense uptake in a choroid plexus papilloma. 
Pretreatment with perchlorate failed to block uptake in this abnor-
mality. A follow-up study several months after radiotherapy is 
shown at bottom. The lesion has decreased in size. The "hot" spot 
on the back of the head is a salivary artifact caused by drooling. 
4. Superficial pathology. The nonspecific uptake 
of radiopertechnetate includes lesions of the skull and 
scalp. Multiple views usually will clarify the prob-
lem since intracerebral abnormalities must be demon-
strable on at least two images obtained at 90° 
angles. Extracerebral but intracranial abnormalities 
such as subdural hematomas, however, do not exhibit 
the finding and may be difficult to differentiate from 
more superficial pathology. Palpation of the scalp 
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and skull radiographs should be used. Bony lesions 
can be elucidated with 99mTc-labeled phosphate 
studies. In addition, serial studies with 99mTc-
pertechnetate over a several-hour period may be 
useful, since most intracranii!l abnormalities show in-
creased uptake with time, while most bone and soft 
tissue lesions seem to lose activity with time (6). 
5. Previous surgery. Surgical flaps and other 
defects may concentrate a tracer and show activity 
for several years after an operation. It is useful to ob-
tain a baseline study shortly after surgery. This makes 
judgments on subsequent studies concerning 
residual or recurrent abnormalities more lucid. 
6. Vertex view artifacts. Mouth activity from the 
tongue and oral mucous membranes may mask a 
frontal lesion. Prior administration of atropine helps 
diminish this. Obvious attention to this use of 
atropine in problems of the elderly, for example, 
glaucoma and urinary retention, should be given . 
Visualization of the stomach on the vertex view in a 
child has been reported to cause some difficulty as 
well, since the appearance on that one view simulated 
a neoplasm. 
7. Need for serial studies after injection. Con-
siderable emphasis has been placed on the need to ob-
tain delayed scintigrams in many intracranial 
problems, such as avascular primary neoplasms, 
metastatic lesions, and extracerebral hematomas. By 
confining the static brain scan to 45- or 60-minute 
Fig 3-Abnormal " mTc-pertechnetate brain image following a 
stannous pyrophosphate bone image. This 4-view static study 2 
days after a pyrophosphate bone scan demonstrates increased ac-
tivity in all vascular structures (sagittal sinus, transverse sinus, 
neck vessels, carotid siphon). The choroid plexus is particularly 
well seen on left lateral view despite perchlorate premedication (see 
text for explanation). 
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Fig 4-Misinjection in cisternography. Six hours after lumbar in-
trathecal administration of 1311-Human Serum Albumin, no in-
tracranial activity was detectable. This scan of the back shows the 
column of tracer split instead of as a solitary column. This is the 
appearance of subdural instead of subarachnoid injection. 
studies, one may miss or have to equivocate on some 
lesions that often are well demonstrated on two- to 
four-hour studies (7,8). 
8. Abnormal pertechnetate brain scans following 
bone scans. Several investigators have reported an 
altered appearance of radiopertechnetate brain scans 
performed one or two days following pyrophosphate 
or polyphosphate bone studies (9, 10, 11). This con-
sisted of abnormally increased activity in the area of 
the sagittal sinus, transverse sinus, and choroid 
plexus (Fig 3). It has been postulated that tin attaches 
to red blood cells following bone imaging and subse-
quently administered pertechnetate undergoes in-
tracellular reduction with labeling of the erythrocytes 
during the brain scan (I 0). It is suggested that brain 
scans should precede pyrophosphate bone scans or, 
alternately, the brain scan, as the second procedure, 
should be performed with 99mTc-DTPA. 
9. Problems with cisternography. Only a couple 
of problems will be discussed here. The first relates to 
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Fig 5-Degradation of bony pelvic structures by bladder activity. 
Upper posterior scintiphoto of pelvis was obtained 2 hours after 
administration of••mTc-polyphosphate. Scatter from intense blad-
der activity severely degrades resolution of surrounding bony 
structures. Marked improvement in image quality is seen after 
patient voided and study was repeated (lower scintiphoto). 
injection technique. If the intrathecally administered 
material (nowadays, primarily m1n-DTPA) is placed 
outside the subarachnoid space, for example, sub- or 
epidural, no activity will reach the head. A scan of the 
back showing a split, rather than solitary, column of 
activity will confirm the suspicion of a faulty injection 
(Fig 4). 
In studying cerebrospinal fluid leaks, it often is 
helpful to examine the patient in the same position in 
which the leak is occurring. A recent report showed 
an interesting artifact caused by residual 99mTc-
pertechnetate activity from the previous day's brain 
scan ( 12). It was in the region of the nasopharynx or 
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mouth, creating the illusion of a CSF leak. Peaking 
solely on the higher gamma photon (247 kev) of 
111 In would guard against this. 
IV. Bone Imaging. Within the past three years, 
bone imaging has changed considerably primarily 
because of the introduction of 99mTc-labeled 
phosphate compounds. Prior to the "phosphate" era, 
Strontium-85 and subsequently 87mSr and 18F were the 
radionuclides used. 
I . Visualization of interfering colon activity with 
85Sr. This is the one difficulty associated with this 
older radiopharmaceutical that will be discussed. 
Because of a persistently high soft tissue and blood 
background, 85Sr studies generally were performed at 
2 to 3 days following injection. At this delayed time, 
the gastrointestinal tract represents the prime mode 
of excretion . Laxatives should be administered prior 
to performance of the study. On occasion, persistent 
colon activity might mimic osseous uptake if it is 
superimposed on a bony region such as the iliac wing. 
I 
rt 
Fig 6-Diffuse bony metastases with relatively normal-appearing 
scan showing " missing kidney" sign . Patient with radiographically 
demonstrated diffuse bony metastases from breast carcinoma. 
Bony structures (except possibly the skull) appear normal on scan. 
The absence of kidney visualization is the prime clue that an ab-
normality is present (see text for further explanation). 
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Repeat study after enema or a couple of days later 
should help differentiate colon from true osseous ac-
tivity. 
2. Diminished resolution of normal pelvic struc-
tures due to bladder activity. This represents a basic 
problem in all imaging procedures. It is particularly 
well demonstrated in this area (Fig 5). The patient 
should be asked to void immediately prior to starting 
the scan. If bladder activity first presents as a 
problem after a study is performed, a repeat examina-
tion of the area after voiding should be obtained. 
3. Marginally active lesions missed due to exces-
sive contrast enhancement. In bone imaging we 
generally are searching for "hot" rather than "cold" 
areas. In setting up a study, the technologist may, in-
advertently, use an extremely active region, such as 
the epiphysis in a child. This might prevent detection 
of an abnormal , but not intensely active, focus in 
another bony area in the same imaging field of view. 
Coned-down camera views of a suspicious area often 
are helpful. 
4. Occasional false-negative studies in purely ly-
tic or diffuse blastic lesions. The exact mechanism of 
uptake of 99mTc-phosphates is unknown. Several 
theories have been advanced which include ion ex-
change, chemisorption, and collagen uptake. In ad-
dition, blood flow and/ or concentration appears to 
play a key role in delivering the radionuclide to the 
Fig 7-"Photon Deficient" bone lesion. The patient was a young 
girl with sickle cell disease and focal pain in distal right femur. 
Anterior, lateral, and anterior pinhole magnification views are 
shown for each distal femur. The area of mottled decreased activity 
("cold" lesion) seen best on right lateral and right anterior pinhole 
collimator views (arrows) is characteristic of bone infarction. 
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Fig 8- Radioactive pulmonary emboli. Anterior, posterior, and 
left lateral lung fields. (See text for explanation). 
abnormal area . Most radiographically lytic lesions 
will have a significant reparative (blastic) component 
on histologic examination which would ensure their 
detection by radionuclide study. On occasion, a 
purely lytic lesion, for example, round cell sarcoma, 
may be relatively quiescent histologically and might, 
therefore, escape scintigraphic detection. 
On the other hand, lesions that tend to have 
diffuse osseous involvement, for example, prostate or 
breast carcinomas, also might give false-negative 
studies (13). In bone scintigraphy, we depend upon a 
gradient between normal and abnormal uptake to 
detect a lesion. In diffuse, uniform involvement, all 
bones may be "hot" and such a gradient may not ex-
ist. One potential clue to the existence of such diffuse 
involvement is a diminution or absence of renal ac-
tivity (Fig 6) ( 14). Approximately 30% to 50% of the 
administered dose of 99mTc-labeled phosphate should 
reach the skeleton with enough of the remaining ac-
tivity going through the kidneys so that renal activity 
on a two-hour study should be fairly intense. 
Conceivably, lesions having hypermetabolic activity 
might utilize more than their usual share of tracer, 
thereby leaving only small amounts for the kidney. 
This finding has been useful to the author and should 
be looked for. 
5. Photon deficient (" cold") lesions. On occasion, 
abnormalities on bone scan may present as "cold" 
rather than "hot" lesions (16). Complete interruption 
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Fig 9-Interference of pleural fluid on dual-headed scanner study. Anterior scan (lower left) shows minimal diminution in right lung perfu-
sion. Posterior scan (lower right) demonstrates much more severe apparent diminution in right lung activity due to interposed pleural fluid 
shown on chest x-ray (see text for explanation). 
of blood supply, as in bone infarction, is a major 
cause of this finding (Fig 7). Other lesions such as oc-
casional metastases and Legg-Calve-Perthes' disease 
in children ( 17) also have shown this finding. In ex-
amining a bone scan, one, therefore, should be aware 
of this alternate evidence of an abnormal lesion. 
6. Asymmetries in chest activity due to radical 
mastectomy. With reduced muscle mass following 
mastectomy, the osseous structures on the involved 
side appear more intense on the anterior scan (15). If 
the asymmetry appears on both anterior and 
posterior studies, a different explanation, such as 
pleural fluid, should be sought. Once again, a history, 
physical, and chest x-ray should solve any problems 
in this regard. 
7. Prosthesis, for example, pacemakers. As in 
brain studies, overlying metallic or bulk objects such 
as pacemakers will attenuate radiation and create a 
void on scan. The characteristic rounded shape of a 
pacemaker should help differentiate it from a possible 
"photon deficient" lesion (see section 5 above). 
8. Femoral vessel activity. Some patients, par-
ticularly in older age groups, will show linear bands 
of increased activity medial to the femoral shafts. It is 
felt that, in some cases, this may represent actual 
changes in the femoral vessel wall. It may or may not 
be associated with radiographic evidence of calcifica-
tion. 
V. Lung Imaging. 
1. Radioactive "pulmonary emboli. " On occa-
sion, large "hot" spots are seen on a lung scan (Fig 8) 
(18). This finding is most often encountered in situa-
tions where difficult venipunctures have allowed ex-
cessive red cell and macroaggregate mixture time 
in the syringe. Larger than usual aggregates ( 100µ to 
1000µ) are formed which lodge in more proximal 
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arterial beds causing these radioactive pulmonary 
emboli. They are not of any clinical consequence, but 
do interfere with interpretation. Their typical ap-
pearance should easily be recognized. 
2. Macroaggregated hold-up on damaged en-
dothelium. Visualization of axillary vessels on the side 
of injection is sometimes noted; particularly in 
patients who have had indwelling venous catheters 
for a few days . The MAA or microspheres adhere to 
the irritated endothelium of these vessels. Throm-
bosed vessels behave in the same fashion. This cannot 
be used as a reliable indicator of lower extremity 
venous thrombosis after foot injection because 
venous stasis or insufficiency from other causes will 
behave similarly ( 19). 
3. Position during injection. Macroaggregated 
albumin distributes along gravitational pathways in 
normal lungs. Therefore, an injection performed in 
an oblique, lateral, or upright position will result in a 
different scan than one performed in a supine or 
prone position . 
4. Perfusion changes due to pulmonary venous 
hypertension. In patients with left ventricular failure 
and mitral heart disease, an anti-gravitational 
phenomenon results in redistribution of perfusion. 
The anterior and upper portions of the lung field will 
exhibit greater activity than the posterior and lower 
portions after a supine injection of MAA or 
microspheres. The degree of change generally is 
related to the severity of the pulmonary venous 
hypertension associated with the disease process. 
5. Free fluid distribution with dual-headed detec-
tors. Free pleural fluid usually gravitates to the 
dependent portion of a hemothorax which is that 
portion away from the detector head of an Anger 
camera or single-head rectilinear scanner. It will, 
therefore, have a minimal effect on the observed per-
fusion pattern. However, when a dual-headed detec-
tor is used, the fluid will be interposed between the 
lung and the lower detector. It often may cause a 
"dampening" effect and an impression of generalized 
decreased perfusion on the posterior scan only (Fig 
9). Adherence to the cardinal rule of not interpreting 
a lung scan without a concurrently obtained chest 
radiograph should help avoid any problems. 
6. Size discrepancies with dual-headed detectors. 
In interpreting lateral lung scans performed with 
dual-headed detectors, one should be aware of a 
"shrunken" appearance occasionally encountered in 
the "down" side of normal lungs. This is actually 
caused by the fact that the "up" side is hyperex-
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panded. The "down" side is actually expanding and 
deflating more than the "up" side. 
7. Loss of activity due to right-to-left shunt. The 
presence of right-to-left cardiac shunts will cause a 
loss of pulmonary activity. The finding of kidney 
activity should arouse some suspicion. In children 
with known large, right-to-left shunts, careful con-
sideration should be given to the advisability of per-
forming the lung scan. The prime reason for this is 
possible complications from the shunting of the 
macroaggregates to the brain . 
In patients who have had surgically created 
shunts, details of the shunt anatomy will help the in-
terpreter of the study determine if the particles are 
distributing the way they should. 
VI. Liver Imaging. 
1. Altered distribution due to colloid particle size. 
Technetium-99m-sulfur colloid particles ( ~ 100-400 
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Fig 10-Subphrenic abscess simulating intrahepatic lesion. On this 
combined anterior liver-lung study, a massive concave defect is 
seen on right lateral border of hepatic activity. It appears as if some 
liver parenchyma is superior to the defect. The initial impression in 
this postoperative febrile patient was that of an intrahepatic 
abscess. At repeat laparotomy, the collection was completely ex-
trahepatic and had displaced the liver medially . 
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mµ) are 10 to 20 times larger than gold-198 colloid 
particles (10-20 mµ). Although the vast majority of 
these larger particles still localize in the liver, a signifi-
cantly greater proportion also will be phagocytized 
by the spleen's reticulo-endothelial system (20). In 
other words, we routinely image the spleen on 99mTc-
sulfur colloid studies, whereas this was not the case 
on 198Au scans. Increased splenic visualization was a 
significant indicator of diminished hepatic perfusion 
on 198Au studies. Because of the normally different 
distribution, this finding is not as sensitive an in-
dicator of decreased liver blood flow on 99mTc-colloid 
studies. 
2. Considerable anatomic variation in normal 
liver. The liver scan is regarded by most nuclear 
medicine physicians as one of the most difficult to in-
terpret. The tremendous variation that one en-
counters in the normal liver is a major contributing 
factor to this problem (21). Such variants as Riedel's 
lobe, left lobe thinning, high hemidiaphragms, inter-
posed colon, and gallbladder fossa must be fully ap-
preciated by the nuclear medicine physician before he 
can interpret hepatic scintigrams intelligently. 
3. Extrinsic pressure deformities from neighbor-
ing organs and structures. Because of its great 
pliability, the liver's shape and configuration may be 
easily altered by normal variants or disease processes 
in neighboring organs and structures (22). Any 
process in the retroperitoneal area, for example, 
kidney or pancreas masses; intraperitoneal area, for 
example, high hepatic flexure of colon or subphrenic 
abscess; or intrahepatic area, for example, dilated 
gallbladder or bile ducts, can cause apparent hepatic 
defects that are often indistinguishable from true in-
trahepatic space-occupying lesions (Fig 10). An ap-
preciation of this possibility and correlation with 
physical findings and other radiographic examina-
tions are helpful in elucidating such problems. 
4. Apparent defects due to attenuation of the 
gamma photons. As in other organ areas, overlying 
objects such as pacemakers, breast prostheses, and 
other objects may cause defects int.he image. Physical 
examination at the time of study will assist the in-
terpreter. 
5. "Pseudomasses" in cirrhosis and hepatitis. 
Focal defects simulating space-occupying lesions may 
be encountered in patients with diffuse parenchymal 
problems such as cirrhosis or hepatitis. In cirrhosis, 
such defects have been attributed to fibrosis, atrophy, 
shunting, and nonfunctioning areas of regenerative 
nodulation (23). The potential existence of a 
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hepatoma in such a "cold" area presents a problem 
that generally may be solved by performing a 
radionuclide angiogram with pertechnetate and/ or 
75Se-selenomethionine or 67Ga-citrate metabolic 
studies. Hepatomas usually will be active with each 
of these tracers while almost all cirrhotic pseudo-
masses will not. 
Less well appreciated is the pseudomass of 
hepatitis which appears to be due to nonuniform in-
volvement of the disease process. Focal, severt swell-
ing of the polygonal cells somehow appears to com-
promise function of much less prevalent R-E cells 
(24) (Fig 11). 
6. Hyperconcentration of colloid in occasional le-
sions. "Hot" spots in the liver have been reported by 
several investigators. Most of these cases have been 
instances of venous obstruction, for example, 
superior vena caval, where umbilical collaterals 
crossing over the anterior surface of the liver in the 
interlobar area locally deposit a large amount of col-
12- 14-72 
Fig. 11-Pseudomass in acute viral hepatitis. Upper row of 99mTc-
sulfur colloid scintiphotos were performed in a 15-year-old, deeply 
jaundiced girl. An apparent space-occupying defect is seen in the 
right lobe. Liver biopsy of this area showed markedly swollen 
hepatocytes and a striking paucity of K upffer's cells. The ap-
pearance was consistent with viral hepatitis. Middle and lower row 
of scintiphotos were obtained 6 weeks and 6 months later, respec-
tively, and show a gradual return to normal. 
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loid (25). Two specific intrahepatic lesions that have 
shown "hot" rather than "cold" areas are abscess 
and hemangioma, the former because of R-E stimula-
tion by the sepsis and the latter because of the 
markedly increased number of venous sinusoids with 
their associated R-E cells. Since we generally think of 
focal hepatic lesions as "cold" areas, one should re-
main attuned to this variant of the abnormal study. 
Recognition of its presence should make one feel a bit 
better after he or she has misinterpreted several 
hepatic masses. 
7. Renal concentration in 1311-rose bengal studies. 
Under normal circumstances, less than 5% of 
radioiodinated rose bengal is excreted by the kidneys. 
In patients with extrahepatic biliary obstruction or 
severe hepatic parenchymal disease, considerably 
more of the activity appears in the urine (26). This is 
particularly true in the former group of patients. 
Most likely it is free 131I dissociated from the rose 
bengal that is appearing in the urine. With higher-
than-normal levels of renal activity, the kidneys may 
be visualized on rose bengal abdominal scans (Fig 
Fig 12-Renal concentration of radioiodinated rose bengal. 
Radioiodinated rose bengal scans on 68-year-old female with pan-
creatic carcinoma. A. t-hr study demonstrates typical pattern of 
renal excretion (arrows). Because of its presence on this early scan, 
confusion with intestinal activity could easily lead to mistaken im-
pression of patent biliary tract. 20/5 min clearance is 24% (normal 
= > 35% ). B. Serial scans, including this 24-hr study, reveal in-
tensification, but no change in position of extrahepatic activity, 
confirming fact that activity represents kidneys (arrows). Upper 
half of right kidney is obscured by overlying hepatic activity. 
Failure of dye to leave liver supports impression of extrahe-
patic obstruction despite moderately impaired liver function 
(20/5-min blood clearance of 24%. C. 24-hr right lateral scan 
shows kidney in normal position posterior to liver. 
FREEMAN: PITFALLS AND ARTIFACTS 
12). This finding must be differentiated from in-
testinal activity to avoid an erroneous interpretation 
of a patent biliary tract. This may be achieved by 
noting the following: 
a. Bilaterality of renal activity 
b. Same position, but more intense activity on 
follow-up studies 
c. Posterior position on lateral study 
d. Same position as kidneys on urogram or 
renal scintigram (if a, b, or c do not answer the 
question) 
8. Altered 131/-rose bengal excretion patterns due 
to fistulae and shunts. In naturally occurring, for ex-
ample, cholecystocolonic, fistula or surgically 
produced shunts, for example, Longmeyer proced~ 
ure, the rose bengal may escape the liver through 
an alternate pathway even though the biliary ducts 
may be obstructed. Careful observation of the time of 
transit as well as the pattern of extrahepatic activity 
are important considerations, as is the presence of a 
surgical history. 
VII. Spleen Imaging. 
1. Bipartite spleen. Similar to other organs, the 
spleen is subject to considerable variation in its nor-
mal shape and configuration. Lobulation and notches 
are frequent findings. On occasion, the spleen pre-
sents in two distinct pieces-the so-called "bipartite" 
spleen. In patients who have had left upper quadrant 
trauma, this may be a particularly troublesome 
finding that may require contrast angiography for 
clarification. 
2. Overlap of left lobe of liver with spleen 
simulating a defect. In many patients the left hepatic 
lobe overlaps the upper splenic border and can cause 
an apparent defect on the superolateral border of the 
spleen (Fig 13). This is a very common pitfall that is 
frequently misinterpreted as a significant splenic le-
sion, particularly in trauma cases. Oblique views may 
not successfully separate the organs. We have found · 
that a 30° caudad-angulated view with the patient in 
the prone position best separates the liver and spleen 
(27). 
3. Accessory spleen masked by overlying left lobe 
of the liver. If a patient has had a therapeutic splenec-
tomy for a hematological disorder, for example, 
idiopathic thrombocytopenia purpura, and continues 
to have difficulties, the presence of an accessory 
spleen must be excluded. Searches for such splenic 
tissue generally are undertaken with 99IllTc-sulfur col-
loid as the initial tracer. Since this radiophar-
maceutical is not spleen-specific, activity in the left 
FREEMAN: PITFALLS AND ARTIFACTS 
Fig 13-0verlap of left hepatic lobe and spleen simulating a 
splenic defect. On the initial study (top) in this 24-year-old male 
with a left upper quadrant stab wound, an apparent defect (arrow) 
is noted in the superolateral margin of the spleen. A slight obli-
quity (bottom) successfully separates left lobe of liver and spleen in-
dicating that the suspect lesion was caused by an overlap of the two 
organs. Note that the medial portion of left lobe of liver (arrow) 
appears thinned due to attenuation of the photons by spine. 
hepatic lobe conceivably might mask a splenunculus. 
Therefore, if the colloid study fails to demonstrate a 
spleen, a repeat study with 99mTc-or 51Cr- labeled to 
heat denatured erythrocytes is needed. The tagged red 
cells are selectively sequestrated by splenic tissue, 
and no interfering hepatic activity is encountered. 
VIII. Pancreas Imaging. 
I. Poor visualization in fasting or debilitated 
patients with a normal pancreas. Poor visualization of 
the pancreas on a 75Se-selenomethionine study may 
reflect either disease or merely not enough pancreatic 
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stimulation (28). The patient should be prepared with 
overnight fasting followed by a well-balanced test 
meal. This will promote a profuse production of pan-
creatic enzymes and good uptake of the 
selenomethionine in most normal individuals (28). 
Absence of activity after such a protocol may be in-
terpreted as pancreatic disease with a greater degree 
of confidence. 
2. Overlapping liver activity. This is particularly 
troublesome in patients with hepatomegaly. Angling 
of the detector head towards the right upper 
quadrant as well as angulating the patient by raising 
the left flank and shoulder is a useful maneuver to 
correct this problem (28). The best solution is the use 
of subtraction technology, if it is available. 
3. Variations in shape and configuration of nor-
mal pancreas. The pancreas may exist in the 
transverse, pistol-shape, oblique, or horseshoe con-
figurations. Sometimes, a defect is present in the mid-
body region as a result of the aorta or spine crossing 
over and thinning out the functioning tissue. Serial 
camera scintiphotos may show a changing concentra-
tion of activity in this region (28). Radionuclide aor-
tography also may be used to correlate the aorta's 
position with the apparent defect on the scintigram. 
IX. Kidney Imaging. 
I. Size discrepancies on erect and prone studies. 
Ptotic kidneys may rotate on anteroposterior axis in 
the erect position. This foreshortening effect creates 
an impression of a smaller kidney when studied in the 
erect or sitting up position. Prone studies provide a 
safer means of assessing renal size. 
2. Free radiopertechnetate in the stomach when 
using 99mTc-labeled agents. Most renal agents are 
prepared by reducing 99mTc from the +7 to +4 
valence state with tin or some other suitable material. 
Pertechnetate ( + 7 state) may persist on rare occa-
sions and its normal biologic localization in gastric 
mucosa may confuse interpretation of left kidney ac-
tivity (29). Similarly, free 1311 may localize in the 
stomach on radioiodinated hippuran renal studies. 
3. Liver accumulation of chlormerodrin in 
azotemia. When 197Hg-chlormerodrin is used in renal 
studies, a small amount of hepatic activity usually is 
present. In azotemic patients, hepatic activity in-
creases at the expense of renal excretion. Merging 
hepatic and renal activity may be misinterpreted as a 
large right kidney. As the azotemia worsens, the 
ability of the kidney to concentrate chlormerodrin is 
completely lost (Fig 14). At this stage, intense liver 
activity may be misinterpreted as a solitary right 
142 
kidney. In severe azotemia, 1311-orthoiodohippurate 
is the agent of choice and its use should avoid any of 
the aforementioned problems (Fig 14). 
4. False results after urography or angiography. 
High doses of organic iodides in the form of 
radiographic contrast media often cause transient 
changes in renal function that will effect the kidn.ey's 
ability to concentrate subsequently administered 
radiopharmaceuticals. This is particularly true in 
patients with obstructive uropathy and, also, after 
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Fig 14-Pitfall in scanning azotemic patients with 197Hg 
chlormerodrin. Patient shown had blood urea nitrogen of 112 
mg/100 ml and plasma creatinine of 5.5 mg/ 100 ml. The "'Hg 
chlormerodrin (top) has all been excreted by the liver. No renal 
concentration is evident. A frequent misinterpretation of this study 
is an enlarged solitary right kidney. The 1311-Hippuran study (bot-
tom) is successfully concentrated in both kidneys which are slightly 
smaller than riormal. 
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selective renal artery studies . Optimally, the 
radionuclide studies should precede the radiographic 
studies. If this is not feasible, an interval of three or 
four days should be obtained between the studies. 
X. Thyroid Imaging. 
1. Poor uptake and image due to saturated iodine 
pool. In patients who have been taking iodide-
contammg medications or who have had 
radiographic examinations with organic iodide con-
trast media, the iodine pool is saturated. Subsequent 
administrations of tracer amounts of radioiodine 
within a few days will result in poor uptakes and im-
ages. 
2. Failure to palpate nodules at the time the scan 
is performed. A vague history of a palpated nodule in 
the right lobe is insufficient data to accurately assess 
whether the nodule is functional or not. Nodules 
should be palpated with the immobilized patient on 
the scanning bed. It should then be transcribed directly 
to the scan image. Such one-to-one relationships are 
best obtained with rectilinear scanner. By knowing 
exactly where a nodule is, one is able to offer an ac-
curate interpretation. In order for a nodule to be con-
sidered functional, it must concentrate greater ac-
tivity than the surrounding tissue. 
3. Pertechnetate uptake in nodules "cold" on 
iodine scans. The categorization of functional or non-
functional nodules is a radioiodine classification . 
Pertechnetate is handled quite differently from iodine 
in that the thyroid traps, but does not organify it. 
Therefore, a nodule may exhibit activity with the 
former, but not the latter (Fig 15). Such a nodule is to 
be considered "cold" and conceivably may represent 
a carcinoma. All nodules of the thyroid should be 
evaluated with radioiodine. 
4. Retrosternal functioning tissue unappreciated 
with low-energy gamma nuclides. lodine-125 has 
achieved some popularity as a thyroid imaging agent. 
Since it possesses very low energy imaging photons 
( ~ 27 kev), it is inappropriate for studies in the 
thorax, for example, to search for retrosternal goiter. 
Although 99mTc-pertechnetate with its 140 kev gam-
ma photon or 1231 with its 190 kev gamma photon 
may suffice, the 364 kev gamma photon of Iodine-
131 appears best for this specific purpose. 
XI. Blood Pool Studies. 
1. Excessive contrast enhancement on rectilinear 
scan cardiac blood pool studies. The detection of a 
pericardia) effusion using the rectilinear scanning 
method depends upon a comparison of the transverse 
diameters of the cardiac blood pool activity and the 
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Fig I 5-Technetium-99m-pertechnetate concentrating in a thyroid 
nodule that is "cold" on Jodine-123 scan. Patient had palpable 
nodule in low lateral portion of left thyroid lobe. The radioiodine 
scintiphoto (bottom) shows this nodule to be hypofunctional 
("cold"), while the pertechnetate study reveals good function in the 
same area. (See text for explanation). The nodule turned out to be 
an adenoma, but the diagnosis of carcinoma could not have been 
excluded. 
cardiac silhouette as seen on a 6-foot supine chest 
radiograph. Excessive contrast enhancement can 
falsely "shrink" the size of the radionuclide blood 
pool and create the erroneous impression of an effu-
sion in cases where it might not exist. 
2. Leakage of pertechnetate into pericardia/ effu-
sions. If 99mTc-pertechnetate is used as the tracer for 
blood pool studies, diagnostic images should be ob-
tained within the first 20 to 30 minutes after injection. 
Studies obtained at one hour or later may be falsely 
negative since pertechnetate slowly diffuses into 
pericardia! effusions masking the "halo" that is 
observed in positive camera studies (30). 
3. Poor labeling of Indium-I I 3m chloride to 
transferrin in patients with receptor site saturation. 
143 
When 113m1n chloride is used as the tracer for a blood 
pool study (particularly placental localization), it 
binds in vivo to transferrin, a serum globulin that is 
essential to the transport of iron. In cases of excessive 
iron ingestion or hemochromatosis, the transferrin 
receptor sites are bound. Subsequently administered 
usmrn chloride will remain unbound and will appear 
in the kidneys. The desired blood pool will not be 
w~ll visualized (31 ). 
Case shown in Figure 8 courtesy Charles J . Blatt, MD. 
Figure 11 is reprinted from the Journal of Nuclear Medicine, 
Vol. 14, No. 8, with ·permission of publisher. 
Figure 13 is reproduced with permission from Radiology 
(110:419-425, 1973). 
Figure 15 is reproduced from Atkins H , The Thyroid 
in Clinical Scintillation Imaging, Freeman LM, Johnson PJ (eds), 
New York, Grune & Stratton, 1975, by permission. 
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administration of 1311 (4), 1231 (5) if available, or 99mTc (6)." 
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how big a dose will now 
bring relie£if it is a narcotic? 
"Tolerance is an ever-present hazard to cont inued 
use of narcotics .... The very first dose diminishes the 
effects of subsequent doses."1 And, as increasing 
amounts of narcotics are required to cont rol pa in, dis-
tressing adverse effects- lethargy, hypotension, con-
stipation, etc.-can needlessly debil itate the patient. 
l.Sadove, M. S.: A look at narcotic and non-narcotic analgesics, Postgrad. 
Med. 49:102 , June 1971. 
how big a dose will now 
bring reliei if it is Talwin®? 
Chances are, the same 50 mg. Talwin Tablet you 
prescribe origina lly wi ll continue to provide good pain 
relief. Ta lwin can be compared to codeine in anal-
gesic efficacy: one 50 mg. tablet appears equivalent 
in analgesic effect to 60 mg. (1 gr.) of codeine. How-
ever, patients receivingTa lwin Tablets for prolonged 
periods face fewer of the consequences you 've come 
to expect with narcotics. There should be fewer 
"adverse effects" on her way of life. 
Tolerance rare: Tolerance to the analgesic effect of 
Ta lwin Tablets is rare. 
Dependence rare: During three years of wide clinical use, there 
have been a few reports of dependence and of withdrawal symp-
toms wi th orally administered Ta/win. Patients with a history 
of drug dependence should be under close supervision while 
receiving Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should 
take precautions to avoid increases in dose by the patient and 
to prevent the use of the drug in anticipation of pain rather 
than for the relief of pain.* 
Generally well tolerated by most patients*: Infrequent ly causes 
decrease in blood pressure or tachycardia; rarely causes respi-
ratory depression or urinary retention; seldom causes diarrhea 
or constipation. Acute, transient CNS effects, described in 
product information on fo llowing page, have occurred in rare 
instances fo llowing the use of Ta lwin Tablets. If dizziness, 
lightheadedness, nausea or vomit ing are encountered, these 
effects may decrease or disappear after the first few doses. 
• see important product information on next page for adverse reactions, patient 
selection, prescribing and precautionary recommendat ions. 
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Talwin® Tablets brand of pentazocine (as hydrochloride) 
Analgesic for Oral Use 
Indication: For the relief of moderate to severe pain. 
Contraindication: Talwin should not be administered to patients 
who are hypersensitive to it. 
Warnings: Drug Dependence. There have been instances of psy-
chological and physical dependence on parenteral Ta/win in pa-
tients with a history of drug abuse and, rarely, in patients without 
such a history. Abrupt discontinuance following the extended use 
of parenteral Ta/win has resulted in withdrawal symptoms. There 
have been a few reports of dependence and of withdrawal symp-
toms with orally administered Ta/win. Patients with a history of 
drug dependence should be under close supervision while receiv-
ing Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should take 
precautions to avoid increases in dose by the patient and to pre-
vent the use of the drug in anticipation of pain rather than for the 
relief of pain. 
Head Injury and Increased lntracranial Pressure. The respiratory 
depressar:t effects of Talwin and its potential for elevating cerebro-
sp;nal fluid pressure may be markedly exaggerated in the pres-
~nce of ~ea~ injury., other intracranial lesions, or a preexisting 
increase in 1ntracran1al pressure. Furthermore, Talwin can pro-
duce effects which may obscure the clinical course of patients 
with head injuries. In such patients, Talwin must be used with 
extreme caution and only if its use is deemed essential. 
Usage in Pregnancy. Safe use of Talwin during pregnancy (other 
than labor) has not been established. Animal reproduction studies 
have not demonstrated teratogenic or embryotoxic effects. How-
ever, Talwin should be administered to pregnant patients (other 
thar: labor) qnly wher:. in the jud~ment of the physician, the po-
tential benefits outweigh the possible hazards. Patients receiving 
Talwin during labor have experienced no adverse effects other 
than those that occur with commonly used analgesics. Talwin 
~hould be used with caution in women delivering premature 
infants. 
Acute CNS Manifestations. Patients receiving therapeutic doses 
of Talwin have experienced, in rare instances, hallucinations (usu-
ally visual), disorientation, and confusion which have cleared 
spontaneously within a period of hours. The mechanism of this 
reaction is not known. Such patients should be very closely ob-
served and vital signs checked . If the drug is reinstituted it should 
be done with caution since the acute CNS manifestations may recur. 
Usage in Children. Because clinical experience in children under 
12 years of age is limited, administration of Talwin in this age 
group is not recommended . 
AmbulaJory Patients. Since sedation, dizziness, and occasional 
euphoria have been noted, ambulatory patients should be warned 
not to operate machinery, drive cars, or unnecessarily expose 
themselves to hazards. 
Precaut~ons: Certain Respiratory Conditions. Although respiratory 
depression has rarely been reported after oral administration of 
T~lwin, t~e drug should .be administered with caution to patients 
with respiratory depression from any cause, severely limited res-
piratory reserve, severe bronchial asthma and other obstructive 
respiratory conditions, or cyanosis. 
Impaired Renal or Hepatic Function. Decreased metabolism of the 
drug by the liver in extensive liver disease may predispose to 
accentuation of side effects. Although laboratory tests have not 
indicated that Talwin causes or !ncreases r~nal or hepatic impair-
ment, the drug should be administered with caution to patients 
with such impairment. 
Myocardial Infarction. As with all drugs, Talwin should be used 
with caution in patients with myocardial infarction who have nau-
sea or vomiting. 
Biliary Surgery. Until further experience is gained with the effects 
of Talwin on the sphincter of Oddi, the drug should be used with 
caution in patients about to undergo surgery of the biliary tract. 
Patients ~eceiving Narcotics . Talwin is a mild narcotic antagonist. 
Some patients previously given .narcotics, including methadone for 
th.e dally treatment of narcotic:: .dependence, have experienced 
withdrawal symptoms after rece1v1ng Talwin. 
CNS Effect. Caution should be used when Talwin is administered 
to patients prone to seizures; seizures have occurred in a few such 
patients in association with the use of Talwin although no cause 
and effect relationship has been established. 
Adverse Reactions: Reactions reported after oral administration of 
Talwi~ ir:clude gastrointestinal:. nausea, vomiting; infrequently 
const1pat1on; and rarely abdominal distress, anorexia diarrhea. 
CNS eftects: dizziness, lighthead.edness, sedation, euphoria, head-
ache; infrequently weakness, disturbed dreams insomnia syn-
cope, visual blurring and focusing difficulty, haf lucinations (see 
Ac.ute .C.NS Ma.nifestatiorys 1:1nder WARNINGS); and rarely tremor, 
1mta~ll1ty, excitement, ~1nn1tus . A1:1tonomic: sweating; infrequently 
flu~hin~; and rarely chills. Allergic: infrequently rash; and rarely 
urt1carii:!, edema of the face. Cardi<;wascu/ar: infrequently de-
crease in blood pressure, tachycardia. Hematologic: rarely de-
pressi~n of white blood cells (especially granulocytes) usual ly 
rev.ers1ble and usually associated with diseases or other drugs 
which ar.e. known to cause su.ch changes, moderate transient 
eos1noph1l1a. Other: rarely respiratory depression urinary reten-
tion, toxic epidermal necrolysis. ' 
Dosage and Administration: Adults. The usual initial adult dose is 
1 tablet (50 mg.) every three or four hours. This may be increased 
to 2 tablets (100 mg.) when needed. Total daily dosage should not 
exceed 600 mg. 
When antiinflammatory or antipyretic effects are desired in addi-
tion to analgesia, aspirin can be administered concomitantly with 
Talwin. 
Children Under 12 Years of Age. Since clinical experience in chil-
dren under 12 years of age is limited, administration of Talwin 
in this age group is not recommended. 
Dura.tion of Therapy. Patients wit.h chronic pain who have received 
Talwin orally for prolonged periods have not experienced with-
~rawal symptoms even when administration was abruptly discon-
tinued (see WARNINGS). No tolerance to the analgesic effect has 
b~en observ~d. Laboratory tests of blood and urine and of liver and 
kidney function have revealed no significant abnormalities after 
prolonged administration of Talwin . 
Overdosage: Manifestations. Clinical experience with Talwin over-
dosage has been insufficient to define the signs of this condition. 
Treatme_nt. Oxygen, intravenous fluids, vasopressors, and other 
supportive measures should be employed as indicated. Assisted 
or controlled ventilation should also be considered. Although 
nalorph1ne and levallorphan are not effective antidotes for respira-
tory . depression due to overdosage or unusual sensitivity to 
Talw1n, P!3ren.teral na.lqxone (Narcan®, avai lable through Endo 
Laboratories) 1s a spec1f1c and effective antagonist. 
Talwin is not subject to narcotic controls. 
How Supplied: Tablets, peach color, scored. Each tablet contains 
Talwin (brand of pentazocine) as hydrochloride equivalent to 
50 mg. base. Bottles of 100. 
Winthrop Laboratories, New York, N.Y. 10016 @~.IZ7:eJ 
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The American Association for the Study of Headache 
announces 
THE ELEVENTH ANNUAL 
HAROLD C. WOLFF, M.D. 
LECTURE AWARD 
which will be awarded to the physician who submits the best original paper on 
headache, head pain, or on the nature of pain itself. The paper may be concerned 
with basic research, clinical studies, or both. All physicians, including those in 
training as fellows or residents are eligible. Winner of the 1975 award is Ottar 
Sjaastad, M.D., Oslo, Norway for his paper, "Histamine and Its Relation to 
Vascular Headache, With Particular Reference to Cluster Headache" 
A prize of $1,000 will be awarded to the recipient of the lectureship, and he will be 
invited to present the paper at the annual meeting of the American Association for 
the Study of Headache. The next annual meeting will be held at the Sheraton-
Dallas Hotel in Dallas, Texas on June 26-27, 1976. 
The papers will be judged by the Editor and Associate Editors of the journal, 
Headache. Papers should be submitted in duplicate in accordance with that jour-
nal's editorial instructions. Those papers which do not win the prize, but which 
are deemed worthy of publication may be published in the journal at the 
discretion of the editorial board. Similarly, authors of these papers may be in-
vited to present their work at the annual meeting, at the discretion of the 
program committee. The judges reserve the right not to make the award if no 
paper submitted is considered worthy of it. 
Papers should be submitted to: 
Otto Appenzeller, M.D., Ph.D. 
Department of Neurology 
UNM School of Medicine 
1007 Stanford Drive N.E. 
Albuquerque , N.M. 87131 
Deadline for submission of papers is March 1, 1976. 
The support of Sandoz Pharmaceuticals is gratefully acknowledged. 
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of theG I The A. H. Robins G .I. Series consists of six book-
lets, designed to provide a Quick, yet comprehen- 1 • 
sive review of basic procedures and practices in S • • G.I. medicine - with particular emphasis on the physical examination as performed in the office or ~ at bedside. If you have teaching responsibilities. er1es limited Quantities are available: Part 1 - lnspeclion, ...:., 
Part 2 - Palpation, Part 3 - Percussion. Part 4 - Auscultation. Part 5 -
Abdominal Pain and Part 6 - Dilferent1al D iagnosis of Abdominal on physical examination 
of the abdomen: 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (A); the lower pole of the 
right kidney (8); the abdominal 
aorta (CJ; the descending colon 
and the sigmoid (DJ; the ascend-
ing colon (E); and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease). 
Impossible to outline, unless 
diseased, distended or enlarged: 
the gallbladder, pancreas. 
stomach, small intestine, trans-
verse colon and spleen. 
Disorders. Write to: The Medical Department, A . H . Robins Company, 
1407 Cummings Drive. Richmond. Virginia 23220. 
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• Brief summary. Adverse Reactions: Blurring of vision. dry mouth, difficult urination. and flushing or dryness of the skin may occur 
on higher dosage levels, rarely on usual dosage Contraindica-
tions: Glaucoma; renal or hepatic disease; obstructive uropathy 
(for example, bladder neck obstruction due to prostatic hyper-
trophy); or hypersensitivity to any of the ingredients. 
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Before prescribing, please consult 
complete product information, a sum-
mary of which follows: 
Indications: Tension and anxiety 
states, somatic complaints which are 
concomitants of emotional factors; psy-
choneurotic states manifested by tension, 
anxiety, apprehension, fatigue, depres-
sive symptoms or agitation; symptomatic 
relief of acute agitation, tremor, delirium 
tremens and hallucinosis due to acute 
alcohol withdrawal; adjunctively in skele-
tal muscle spasm due to reflex spasm to 
local pathology, spasticity caused by 
upper motor neuron disorders, athetosis, 
stiff-man syndrome, convulsive disorders 
(not for sole therapy) . 
Contraindicated: Known hyperserisi-
tivity to the drug. Children under 6 
months of age. Acute narrow angle glau-
coma; may be used in patients with open 
angle glaucoma who are receiving appro-
priate therapy. 
Warnings: Not of value in psychotic 
patients. Caution against hazardous 
occupations requiring complete mental 
alertness. When used adjunctively in con-
vulsive disorders, possibility of increase 
in frequency and/ or severity of grand mal 
seizures may require increased dosage of 
standard anticonvulsant medication; 1~1~~ 
abrupt withdrawal may be associated 
with temporary increase in frequency 
and/ or severity of seizures. Advise 
against simultaneous ingestion of alcohol 
and other CNS depressants. Withdrawal 
symptoms (similar to those with barbitu-
rates and alcohol) have occurred follow-
ing abrupt discontinuance (convulsions, 
tremor, abdominal and muscle cramps, 
vomiting and sweating). Keep addiction-
prone individuals under careful surveil-
lance because of their predisposition to 
habituation and dependence. In preg-
nancy, lactation or women of childbearing 
age, weigh potential benefit against 
possible hazard. 
Precautions: If combined with other 
psychotropics or anticonvultants, con-
sider carefully pharmacology of agents 
employed; drugs such as phenothiazines, 
narcotics, barbiturates, MAO inhibitors 
and other antidepressants may potentiate 
its action. Usual precautions indicated in 
patients severely depressed, or with latent 
depression, or with suicidal tendencies. 
Observe usual precautions in impaired 
renal or hepatic function. Limit dosage to 
smallest effective amount in elderly and 
debilitated to preclude ataxia or over-
sedation. 
Side Effects: Drowsiness, confusion, 
diplopia, hypotension, changes in libido, 
nausea, fatigue, depression, dysarthria, 
jaundice, skin rash, ataxia, constipation, 
headache, incontinence, changes in sali-
vation, slurred speech, tremor, vertigo, 
urinary retention, blurred vision. Para-
doxical reactions such as acute hyper-
excited states, anxiety, hallucinations, 
increased muscle spasticity, insomnia, 
rage, sleep disturbances, stimulation 
have been reported; should these occur, 
discontinue drug. Isolated reports of neu-
tropenia, jaundice; periodic blood counts 
and liver function tests advisable during 
long-term therapy. 
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When, for example, despite counseling, 
tension and anxiety continue to produce 
distressing somatic symptoms 
. Promnt action 
is a gooll reason to 
consider Valium 
(diazepam) 
2-mg, 5-mg, 10-mg tablets 
